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Summary of findings {#CD002003-sec1-0001}
===================

###### Beta‐blockers versus placebo as first‐line therapy for hypertension

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ----------------------------------- ---------------------------------------- -----------------------
  **Beta‐blockers versus placebo as first‐line therapy for hypertension**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  **Participants:** people with hypertension  **Settings:** high‐income countries, mainly Western Europe and North America  **Intervention:** beta‐blockers  **Comparison:** placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**     **No of participants  (studies)**   **Certainty of the evidence  (GRADE)**   
  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **Corresponding risk**                                                                                                                                         
  **Placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **Beta‐blockers**                                                                                                                                              
  **Total mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **52 per 1000**                                 **51 per 1000**   (46 to 57)      **RR 0.99**   (0.88 to 1.11)        23613  (4 studies)                       ⊕⊕⊕⊝  **Moderate**^1^
  **Total cardiovascular disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **64 per 1000**                                 **57 per 1000**   (51 to 63)      **RR 0.88**   (0.79 to 0.97)        23613  (4 studies)                       ⊕⊕⊝⊝  **Low**^1,2^
  **Total stroke**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **23 per 1000**                                 **18 per 1000**   (15 to 22)      **RR 0.80**   (0.66 to 0.96)        23613  (4 studies)                       ⊕⊕⊝⊝  **Low**^1,2^
  **Total coronary heart disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **37 per 1000**                                 **34 per 1000**   (30 to 40)      **RR 0.93**   (0.81 to 1.07)        23613  (4 studies)                       ⊕⊕⊕⊝  **Moderate**^1^
  **Withdrawal due to adverse effect**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **74 per 1000**                                 **249 per 1000**   (60 to 1000)   **RR 3.38**   (0.82 to 13.95)       22729  (3 studies)                       ⊕⊕⊝⊝  **Low**^3^
  \*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** confidence interval; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                         
  GRADE Working Group grades of evidence  **High certainty:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate certainty:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low certainty:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low certainty:** We are very uncertain about the estimate.                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ----------------------------------- ---------------------------------------- -----------------------

^1^ The two studies that contribute to the most weight of the pooled RR have high risk of bias (especially incomplete outcome reporting due to attrition bias): downgraded by 1 point.  ^2^ The RR is too close to 1 and could easily include 1 if more trials are added: downgraded by 1 point.  ^3^ Inconsistent results across studies (I^2^ = 100%): downgraded by 2 points.

###### Beta‐blockers compared to diuretics as first‐line therapy for hypertension

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ----------------------------------- ---------------------------------------- -----------------------
  **Beta‐blockers compared to diuretics as first‐line therapy for hypertension**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  **Participants:** people with hypertension  **Settings:** high‐income countries, mainly Western Europe and North America  **Intervention:** beta‐blockers  **Comparison:** diuretics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**     **No of participants  (studies)**   **Certainty of the evidence  (GRADE)**   
  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **Corresponding risk**                                                                                                                                         
  **Diuretics**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     **Beta‐blockers**                                                                                                                                              
  **Total mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **41 per 1000**                                 **43 per 1000**   (37 to 49)      **RR 1.04**   (0.91 to 1.19)        18241  (5 studies)                       ⊕⊕⊕⊝  **Moderate**^1^
  **Total cardiovascular disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **45 per 1000**                                 **51 per 1000**   (45 to 58)      **RR 1.13**   (0.99 to 1.28)        18135  (4 studies)                       ⊕⊕⊕⊝  **Moderate**^1^
  **Total stroke**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **12 per 1000**                                 **14 per 1000**   (8 to 25)       **RR 1.17**   (0.65 to 2.09)        18135  (4 studies)                       ⊕⊕⊝⊝  **Low**^1,2^
  **Total coronary heart disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **33 per 1000**                                 **37 per 1000**   (27 to 50)      **RR 1.12**   (0.82 to 1.54)        18135  (4 studies)                       ⊕⊕⊝⊝  **Low**^1,2^
  **Withdrawal due to adverse effect**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **109 per 1000**                                **184 per 1000**   (104 to 327)   **RR 1.69**   (0.95 to 3.00)        11566  (3 studies)                       ⊕⊕⊝⊝  **Low**^1,2^
  \*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** confidence interval; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                         
  GRADE Working Group grades of evidence  **High certainty:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate certainty:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low certainty:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low certainty:** We are very uncertain about the estimate.                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ----------------------------------- ---------------------------------------- -----------------------

^1^ The two studies that contribute to the most weight of the pooled RR have high risk of bias (especially incomplete outcome reporting due to attrition bias): downgraded by 1 point.  ^2^ Inconsistent results across studies (I^2^ = 73% for stroke, 66% for coronary heart disease, and 95% for adverse effects): downgraded by 1 point.

###### Beta‐blockers compared to calcium‐channel blockers as first‐line therapy for hypertension

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------------- ---------------------------------------- -----------------------
  **Beta‐blockers compared to calcium‐channel blockers as first‐line therapy for hypertension**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **Participants:** people with hypertension  **Settings:** high‐income countries, mainly Western Europe and North America  **Intervention:** beta‐blockers  **Comparison:** calcium‐channel blockers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**   **No of participants  (studies)**   **Certainty of the evidence  (GRADE)**   
  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **Corresponding risk**                                                                                                                                       
  **Calcium‐channel blockers**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Beta‐blockers**                                                                                                                                            
  **Total mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **73 per 1000**                                 **78 per 1000**   (73 to 83)    **RR 1.07**   (1.0 to 1.14)         44825  (4 studies)                       ⊕⊕⊕⊝  **Moderate**^1^
  **Total cardiovascular disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **81 per 1000**                                 **96 per 1000**   (87 to 104)   **RR 1.18**   (1.08 to 1.29)        19915  (2 studies)                       ⊕⊕⊕⊝  **Moderate**^2^
  **Total stroke**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **23 per 1000**                                 **29 per 1000**   (26 to 32)    **RR 1.24**   (1.11 to 1.4)         44167  (3 studies)                       ⊕⊕⊕⊝  **Moderate**^3^
  **Total coronary heart disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **39 per 1000**                                 **41 per 1000**   (37 to 45)    **RR 1.05**   (0.96 to 1.15)        44167  (3 studies)                       ⊕⊕⊕⊝  **Moderate**^3^
  **Withdrawal due to adverse effect**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **33 per 1000**                                 **40 per 1000**   (23 to 67)    **RR 1.20**   (0.71 to 2.04)        21591  (2 studies)                       ⊕⊕⊝⊝  **Low**^2,4^
  \*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** confidence interval; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                       
  GRADE Working Group grades of evidence  **High certainty:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate certainty:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low certainty:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low certainty:** We are very uncertain about the estimate.                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------------- ---------------------------------------- -----------------------

^1^ The RR is too close to 1 and could easily include 1 if more trials are added: downgraded by 1 point.

^2^ Only 2 hypertension trials comparing beta‐blockers to calcium‐channel blockers have reported data on this outcome: downgraded by 1 point.  ^3^ Only 3 hypertension trials comparing beta‐blockers to calcium‐channel blockers have reported data on this outcome: downgraded by 1 point.

^4^ Inconsistent results across studies (I^2^ = 93%): downgraded by 1 point.

###### Beta‐blockers compared to renin‐angiotensin system inhibitors as first‐line therapy for hypertension

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ----------------------------------- ---------------------------------------- -----------------------
  **Beta‐blockers compared to renin‐angiotensin system inhibitors as first‐line therapy for hypertension**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  **Participants:** people with hypertension  **Settings:** high‐income countries, mainly Western Europe and North America  **Intervention:** beta‐blockers  **Comparison:** renin‐angiotensin system inhibitors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**     **No of participants  (studies)**   **Certainty of the evidence  (GRADE)**   
  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **Corresponding risk**                                                                                                                                         
  **Renin‐angiotensin system inhibitors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **Beta‐blockers**                                                                                                                                              
  **Total mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **84 per 1000**                                 **92 per 1000**   (82 to 104)     **RR 1.10**   (0.98 to 1.24)        10828  (3 studies)                       ⊕⊕⊕⊝  **Moderate**^1^
  **Total cardiovascular disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **115 per 1000**                                **115 per 1000**   (83 to 159)    **RR 1.0**   (0.72 to 1.38)         10828  (3 studies)                       ⊕⊕⊝⊝  **Low**^1,2^
  **Total stroke**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **51 per 1000**                                 **66 per 1000**   (56 to 77)      **RR 1.30**   (1.11 to 1.53)        9951  (2 studies)                        ⊕⊕⊕⊝  **Moderate**^3^
  **Total coronary heart disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **54 per 1000**                                 **49 per 1000**   (41 to 57)      **RR 0.90**   (0.76 to 1.06)        9951  (2 studies)                        ⊕⊕⊝⊝  **Low**^3,4^
  **Withdrawal due to adverse effect**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **137 per 1000**                                **194 per 1000**   (177 to 211)   **RR 1.41**   (1.29 to 1.54)        9951  (2 studies)                        ⊕⊕⊕⊝  **Moderate**^3^
  \*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** confidence interval; **RR:** risk ratio.                                                                                                                                                                                                                                                                                                                                                         
  GRADE Working Group grades of evidence  **High certainty:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate certainty:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low certainty:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low certainty:** We are very uncertain about the estimate.                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ----------------------------------- ---------------------------------------- -----------------------

^1^ Only 3 hypertension trials comparing beta‐blockers to RAS inhibitors have reported data on this outcome: downgraded by 1 point.  ^2^ Inconsistent results across studies (I^2^ = 74%): downgraded by 1.  ^3^ Only 2 hypertension trials comparing beta‐blockers to RAS inhibitors have reported data on this outcome: downgraded by 1 point.

^4^ Imprecise results, as the effect ranges from a clinically important benefit to a small increase in harm: downgraded by 1 point.

Background {#CD002003-sec1-0002}
==========

Description of the condition {#CD002003-sec2-0001}
----------------------------

Hypertension is one of the leading causes of disability and premature deaths worldwide ([GBD 2015](#CD002003-bbs2-0057){ref-type="ref-list"}). The rationale for treating hypertension achieved great impetus with the finding that even small reductions in blood pressure can significantly reduce associated morbidity and mortality risks ([Collins 1990](#CD002003-bbs2-0052){ref-type="ref-list"}; [Staessen 2003](#CD002003-bbs2-0095){ref-type="ref-list"}; [Thomopoulos 2015](#CD002003-bbs2-0096){ref-type="ref-list"}). The major classes of drugs for treating hypertension include beta‐blockers, calcium‐channel blockers (CCBs), diuretics, and renin‐angiotensin system (RAS) inhibitors ([Wiysonge 2013](#CD002003-bbs2-0111){ref-type="ref-list"}).

Description of the intervention {#CD002003-sec2-0002}
-------------------------------

Beta‐blockers refer to a diverse group of drugs which block the action of endogenous catecholamines on beta‐adrenergic receptors, part of the autonomic (or sympathetic) nervous system ([Wiysonge 2007a](#CD002003-bbs2-0101){ref-type="ref-list"}). The autonomic nervous system has been known to play a role in blood pressure control since 1949 ([Smithwick 1949](#CD002003-bbs2-0094){ref-type="ref-list"}). The principal adrenergic receptors present in the human cardiovascular system are the β1, β2, and α1 receptors ([Fergus 2015](#CD002003-bbs2-0056){ref-type="ref-list"}; [Pucci 2016](#CD002003-bbs2-0089){ref-type="ref-list"}). Beta‐blockers vary in their β1/β2‐adrenergic receptor selectivity and vasodilatory properties, and this diversity has given rise to their classification into first, second, and third generation. First‐generation beta‐blockers exercise identical affinity for β1 and β2 receptors and are thus classified as non‐selective beta‐blockers (e.g. propranolol). Second‐generation beta‐blockers are more attracted to β1 than β2 receptors, and are thus termed selective beta‐blockers (e.g. atenolol). The third‐generation of beta‐blockers are known for their intrinsic vasodilatory properties (e.g. nebivolol) ([Weber 2005](#CD002003-bbs2-0099){ref-type="ref-list"}).

How the intervention might work {#CD002003-sec2-0003}
-------------------------------

Beta‐blockers have been used as first‐line therapy for hypertension since the late 1960s, apparently because activation of the sympathetic nervous system is important in the aetiology and maintenance of hypertension ([Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [JNC‐6 1997](#CD002003-bbs2-0065){ref-type="ref-list"}; [Larochelle 2014](#CD002003-bbs2-0070){ref-type="ref-list"}; [Philipp 1997](#CD002003-bbs2-0085){ref-type="ref-list"}; [Psaty 1997](#CD002003-bbs2-0088){ref-type="ref-list"}; [Ramsay 1999](#CD002003-bbs2-0090){ref-type="ref-list"}; [Wiysonge 2013](#CD002003-bbs2-0111){ref-type="ref-list"}); but the robustness of the evidence for use of beta‐blockers as first‐line therapy for hypertension without compelling indications is controversial ([Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}; [Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}; [Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}; [Messerli 2003](#CD002003-bbs2-0075){ref-type="ref-list"}; [Opie 1997](#CD002003-bbs2-0079){ref-type="ref-list"}; [Opie 2014](#CD002003-bbs2-0082){ref-type="ref-list"}; [Wiysonge 2007a](#CD002003-bbs2-0101){ref-type="ref-list"}; [Wright 2000](#CD002003-bbs2-0105){ref-type="ref-list"}). From 2004 to 2006, three meta‐analyses were published which found that beta‐blockers were less effective in reducing the incidence of stroke ([Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}), and the composite of major cardiovascular outcomes including stroke, myocardial infarction, and death ([Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}), compared to all drugs for treating hypertension. However, beta‐blockers might have different comparative outcomes versus the various other classes of drugs. For instance, several studies have claimed that CCBs are better than other antihypertensive agents in preventing stroke but less good at preventing coronary heart disease (CHD; [Angeli 2004](#CD002003-bbs2-0042){ref-type="ref-list"}; [Opie 2002](#CD002003-bbs2-0080){ref-type="ref-list"}; [Verdecchia 2005](#CD002003-bbs2-0098){ref-type="ref-list"}). Thus, it is important to know to what extent the comparisons made by Lindholm and colleagues ([Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}; [Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}) and Khan and co‐authors ([Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}; [Kuyper 2014](#CD002003-bbs2-0069){ref-type="ref-list"}) relate to beta‐blockers versus specific classes of antihypertensive drugs such as diuretics, CCBs, or RAS inhibitors. RAS inhibitors refer to angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin inhibitors (DRI). In general, beta‐blockers might be better or worse than one specific class of drugs for specific endpoints so that comparing beta‐blockers with all other classes could be misleading ([Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}; [Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}; [Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}). In addition, the safety of a medication is as important to the clinician and the person as is the effectiveness; but neither Lindholm and colleagues ([Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}; [Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}) nor Khan and co‐authors ([Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}; [Kuyper 2014](#CD002003-bbs2-0069){ref-type="ref-list"}) provided data on this aspect when comparing beta‐blockers to other antihypertensive agents (see also [Table 9](#CD002003-tbl-0009){ref-type="table"}).

###### Previous systematic reviews of beta‐blockers as first‐line hypertension therapy

  ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Identification**                                          **Comparison**                                                                                                              **Trials included**                                                                                                                                                                                            **Comments**

  [Psaty 1997](#CD002003-bbs2-0088){ref-type="ref-list"}      Beta‐blocker vs placebo                                                                                                     MRC 1985; MRCOA 1992; Coope 1986; STOP 1991 trials                                                                                                                                                             STOP 1991 classified as beta‐blocker trial as 68% in active group were taking a beta‐blocker.

  [Messerli 1998](#CD002003-bbs2-0074){ref-type="ref-list"}   Beta‐blocker vs placebo in older people                                                                                     Coope 1986; MRCOA 1992                                                                                                                                                                                         The review concluded that beta‐blockers should not be used in elderly people with hypertension.

  [Wright 1999](#CD002003-bbs2-0104){ref-type="ref-list"}     Beta‐blocker vs diuretic                                                                                                    Berglund 1981; HAPPHY 1987; MRC 1985; MRCOA 1992; VA COOP 1982                                                                                                                                                 IPPPSH not included because 67% of participants taking beta‐blocker were taking a diuretic.

  [Wright 2000](#CD002003-bbs2-0105){ref-type="ref-list"}     Beta‐blocker vs placebo                                                                                                     MRC 1985; MRCOA 1992                                                                                                                                                                                           Coope 1986 and STOP excluded because of high use of diuretic.

  [Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}   Atenolol vs placebo, and atenolol vs other antihypertensive drugs                                                           Placebo: Coope 1986; MRCOA 1992; Dutch TIA 1993; TEST 1995)\                                                                                                                                                   Included trials in which only a proportion (\> 50%) of participants were assigned to start treatment with atenolol.
                                                                                                                                                                                          Other antihypertensive drugs: HAPPHY 1987; MRCOA 1992; UKPDS‐39‐1998; LIFE 2002; ELSA 2002                                                                                                                     

  [NICE 2004](#CD002003-bbs2-0077){ref-type="ref-list"}       Beta‐blockers vs placebo, thiazide diuretics, calcium‐channel blockers, ACE inhibitors, and angiotensin receptor blockers   Placebo: IPPPSH 1985; MRC 1985; Coope 1986; MRCOA 1992; Dutch TIA 1993; TEST 1995; STOP‐2 1999\                                                                                                                Included MAPPHY which is a subset of HAPPHY study. Included some studies in which only a proportion of participants were assigned to start treatment on a beta‐blocker.
                                                                                                                                                                                          Thiazide diuretics: MRC 1985; HAPPHY 1987; MAPHY 1988; MRCOA 1992\                                                                                                                                             
                                                                                                                                                                                          Calcium‐channel blockers: CONVINCE 1998; STOP‐2 1999; NORDIL 2000; ELSA 2002; INVEST 2003\                                                                                                                     
                                                                                                                                                                                          ACE inhibitors: CAPP 1999; STOP‐2 1999\                                                                                                                                                                        
                                                                                                                                                                                          Angiotensin receptor blockers: LIFE 2002                                                                                                                                                                       

  [Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}    Beta‐blocker vs placebo, and beta‐blocker vs other antihypertensive drugs                                                   Placebo: IPPPSH 1985; MRC 1985; Coope 1986; MRCOA 1992; Dutch TIA 1993; TEST 1995\                                                                                                                             Included trials in which only a proportion (\> 50%) of participants were assigned to start treatment with a beta‐blocker.
                                                                                                                                                                                          Other antihypertensive drugs: Berglund 1981; MRC 1985; HAPPHY 1987; STOP 1991; MRCOA 1992; Yurenev 1992; UKPDS‐39‐1998; STOP‐2 1999; NORDIL 2000; LIFE 2002; ELSA 2002; CONVINCE 2003; ASCOT 2005              

  [Bradley 2006](#CD002003-bbs2-0108){ref-type="ref-list"}    Beta‐blocker vs placebo, diuretics, calcium‐channel blockers, and renin‐angiotensin system inhibitors                       Placebo: IPPPSH 1985; MRC 1985; Coope 1986; MRCOA 1992\                                                                                                                                                        Excluded Dutch TIA 1993 and TEST 1995 because not all participants in these 2 trials were had hypertension.
                                                                                                                                                                                          Diuretics: Berglund 1981; VA COOP 1982; MRC 1985; HAPPHY 1987; MRCOA 1992\                                                                                                                                     
                                                                                                                                                                                          Calcium‐channel blockers: AASK 2002; ELSA 2002; INVEST 2003; ASCOT 2005\                                                                                                                                       
                                                                                                                                                                                          Renin‐angiotensin system inhibitors: UKPDS‐39‐1998; AASK 2002; LIFE 2002                                                                                                                                       

  [Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}       Beta‐blocker vs placebo, and beta‐blocker vs other antihypertensive drugs                                                   Placebo: IPPPSH 1985; MRC 1985; Coope 1986; MRCOA 1992; Dutch TIA 1993; TEST 1995\                                                                                                                             Included trials in which only a proportion (\> 50%) of participants were assigned to start treatment with a beta‐blocker.
                                                                                                                                                                                          Other antihypertensive drugs: Berglund 1981; MRC 1985; HAPPHY 1987; STOP 1991; MRCOA 1992; Yurenev 1992; UKPDS‐39‐1998; STOP‐2 1999; CAPP 1999; NORDIL 2000; LIFE 2002; ELSA 2002; CONVINCE 2003; ASCOT 2005   

  [NICE 2006](#CD002003-bbs2-0078){ref-type="ref-list"}       Beta‐blockers vs thiazide diuretics, calcium‐channel blockers, ACE inhibitors, and angiotensin receptor blockers            Thiazide diuretics: MRC 1985; HAPPHY 1987; MRCOA 1992\                                                                                                                                                         Updated NICE 2004 review by evaluating head‐to‐head trials only. ASCOT new study added and excluded CONVINCE; NORDIL; and CAPP due to confounded use.
                                                                                                                                                                                          Calcium‐channel blockers: ASCOT 2005; ELSA 1992; INVEST 2003\                                                                                                                                                  
                                                                                                                                                                                          ACE inhibitors: no studies meeting criteria\                                                                                                                                                                   
                                                                                                                                                                                          Angiotensin receptor blockers: LIFE 2002                                                                                                                                                                       

  [Dahlöf 2007](#CD002003-bbs2-0053){ref-type="ref-list"}     Beta‐blockers with or without diuretics vs placebo or no treatment                                                          Coope 1986; MRC 1985; MRCOA 1992; STOP 1991; UKPDS‐39                                                                                                                                                          IPPPSH 1985 not included. STOP 1991 included because \> 85% of participants on active treatment received beta‐blocker as first‐line or second‐line therapy. Regarded the \'control group\' in the UKPDS‐39 as placebo, even though the group permitted antihypertensive therapy (other than  ACE inhibitors and beta‐blockers), because the target for blood pressure reduction was not as low as in the beta‐blocker group.

  [Wright 2009](#CD002003-bbs2-0106){ref-type="ref-list"}     Beta‐blocker vs placebo                                                                                                     MRC 1985; MRCOA 1992; Dutch TIA 1993; TEST 1995; UKPDS‐39 1998                                                                                                                                                 IPPPSH 1985 and Coope 1986 excluded because of high use of diuretics in beta‐blocker group. UKPDS‐39 included using \'less tight control group\' as placebo, but participants took antihypertensive treatments for 57% of total person‐years.

  [Wiysonge 2012](#CD002003-bbs2-0110){ref-type="ref-list"}   Beta‐blocker vs placebo, diuretics, calcium‐channel blockers, and renin‐angiotensin system inhibitors                       Placebo: IPPPSH 1985; MRC 1985; Coope 1986; MRCOA 1992\                                                                                                                                                        Previously published version of this systematic review
                                                                                                                                                                                          Diuretics (Berglund 1981; VA COOP 1982; MRC 1985; HAPPHY 1987; MRCOA 1992\                                                                                                                                     
                                                                                                                                                                                          Calcium‐channel blockers: AASK 2002; ELSA 2002; INVEST 2003; ASCOT 2005\                                                                                                                                       
                                                                                                                                                                                          Renin‐angiotensin system inhibitors: UKPDS‐39‐1998; AASK 2002; LIFE 2002                                                                                                                                       

  [Kuyper 2014](#CD002003-bbs2-0069){ref-type="ref-list"}     Beta‐blocker vs placebo, and beta‐blocker vs other antihypertensive drugs                                                   Placebo: IPPPSH 1985; MRC 1985; Coope 1986; STOP 1991; MRCOA 1992; Dutch TIA 1993; TEST 1995\                                                                                                                  Compared the efficacy of atenolol vs non‐atenolol beta‐blockers in clinical trials enrolling young (aged \< 60 years) and older people with hypertension.\
                                                                                                                                                                                          Other antihypertensive drugs: Berglund 1981; MRC 1985; HAPPHY 1987; STOP 1991; MRCOA 1992; Yurenev 1992; UKPDS‐39‐1998; STOP‐2 1999; CAPP 1999; NORDIL 2000; LIFE 2002; ELSA 2002; CONVINCE 2003; ASCOT 2005   The review concluded that atenolol should not be used in  older people with hypertension but class effect uncertain, and beta‐blockers reasonable option for the young.

  Wiysonge 2017                                               Beta‐blocker vs placebo, diuretics, calcium‐channel blockers, and renin‐angiotensin system inhibitors                       Placebo: IPPPSH 1985; MRC 1985; Coope 1986; MRCOA 1992\                                                                                                                                                        Current systematic review
                                                                                                                                                                                          Diuretics: Berglund 1981; VA COOP 1982; MRC 1985; HAPPHY 1987; MRCOA 1992\                                                                                                                                     
                                                                                                                                                                                          Calcium‐channel blockers: AASK 2002; ELSA 2002; INVEST 2003; ASCOT 2005\                                                                                                                                       
                                                                                                                                                                                          Renin‐angiotensin system inhibitors: UKPDS‐39‐1998; AASK 2002; LIFE 2002                                                                                                                                       
  ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACE: angiotensin‐converting enzyme.

Why it is important to do this review {#CD002003-sec2-0004}
-------------------------------------

Proper understanding of the evidence for beta‐blocker therapy in hypertension requires a regularly updated systematic, comprehensive, and appropriate analysis of all currently available data. In 2007, we published a Cochrane Review which re‐assessed the place of beta‐blockers as first‐line therapy for hypertension relative to each of the other major classes of antihypertensive drugs. An update of the review was published in 2012. The current review is an update of the 2012 review.

Objectives {#CD002003-sec1-0003}
==========

To assess the effects of beta‐blockers on morbidity and mortality endpoints in adults with hypertension.

Methods {#CD002003-sec1-0004}
=======

Criteria for considering studies for this review {#CD002003-sec2-0005}
------------------------------------------------

### Types of studies {#CD002003-sec3-0001}

Randomised controlled trials (RCTs) with a duration of one year or more.

### Types of participants {#CD002003-sec3-0002}

Men and non‐pregnant women, aged 18 years and over, with hypertension as defined by cut‐off points operating at the time of the study under consideration.

### Types of interventions {#CD002003-sec3-0003}

The treatment group must have received a beta‐blocker drug either as monotherapy or as a first‐line drug in a stepped‐care approach. The control group could have been a placebo, no treatment, or another antihypertensive drug (including a different beta‐blocker or the same beta‐blocker at a different dose).

### Types of outcome measures {#CD002003-sec3-0004}

#### Primary outcomes {#CD002003-sec4-0001}

Mortality.

#### Secondary outcomes {#CD002003-sec4-0002}

Total (i.e. fatal and non‐fatal) stroke.Total coronary heart disease (myocardial infarction, sudden death).Total cardiovascular disease (CVD: i.e. fatal and non‐fatal CHD, stroke, congestive heart failure, and transient ischaemic attacks).Adverse events leading to discontinuation of allocated treatment.Degree of reduction in systolic and diastolic blood pressure achieved by beta‐blocker therapy in relation to each comparator treatment.

We used the definitions employed by the investigators of the study under consideration.

Search methods for identification of studies {#CD002003-sec2-0006}
--------------------------------------------

### Electronic searches {#CD002003-sec3-0005}

The Cochrane Hypertension Information Specialist conducted systematic searches in the following databases for randomised controlled trials without language, publication year or publication status restrictions:

the Cochrane Hypertension Specialised Register via the Cochrane Register of Studies (CRS‐Web) (searched 14 June 2016);the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 6) via the Cochrane Register of Studies (CRS‐Web) (searched 14 June 2016);MEDLINE Ovid (from 1946 onwards), MEDLINE Ovid Epub Ahead of Print, and MEDLINE Ovid In‐Process & Other Non‐Indexed Citations (searched 14 June 2016);Embase Ovid (searched 14 June 2016);ClinicalTrials.gov ([www.clinicaltrials.gov](www.clinicaltrials.gov)) searched 14 June 2016);

The Information Specialist modelled subject strategies for databases on the search strategy designed for MEDLINE. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled (as described in the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011)). Search strategies from 19 January 2015 are found in [Appendix 1](#CD002003-sec2-0016){ref-type="app"}. Search strategies for all major databases are provided in [Appendix 2](#CD002003-sec2-0017){ref-type="app"}.

Searches for previous versions of the review were conducted in June 2006, May 2011, December 2011, and November 2012 ([Bradley 2006](#CD002003-bbs2-0108){ref-type="ref-list"}; [Wiysonge 2007b](#CD002003-bbs2-0109){ref-type="ref-list"}; [Wiysonge 2012](#CD002003-bbs2-0110){ref-type="ref-list"}; [Wiysonge 2013](#CD002003-bbs2-0111){ref-type="ref-list"}). In the previous search conducted in June 2006 ([Bradley 2006](#CD002003-bbs2-0108){ref-type="ref-list"}; [Wiysonge 2007b](#CD002003-bbs2-0109){ref-type="ref-list"}), we searched PubMed, Embase, Cochrane Database of Systematic Reviews, and the York Database of Abstracts of Reviews of Effectiveness for previous reviews and meta‐analyses of antihypertensive treatments that included beta‐blockers. Reports of relevant trials referred to in these reviews were obtained. We then carried out an exhaustive search for eligible RCTs in MEDLINE (for the period 1966 to June 2006) using the terms \"adrenergic beta‐antagonists\" \[MESH\], \"beta (blockers)\" and exp \"hypertension\" \[MESH\] combined with the optimally sensitive strategy for identifying RCTs recommended by Cochrane ([Higgins 2011](#CD002003-bbs2-0061){ref-type="ref-list"}); Embase (for the period 1980 to June 2006) using a search strategy similar to that used for MEDLINE; and CENTRAL (the Cochrane Library, 2016, Issue 2). Finally, experts in the field of hypertension and drug companies manufacturing beta‐blockers were contacted for unpublished trials. After reaching consensus on the search strategy for each electronic database, the information specialist of the South African Cochrane Centre conducted the respective electronic searches.

### Searching other resources {#CD002003-sec3-0006}

The Cochrane Hypertension Information Specialist searched the Hypertension Specialised Register segment (which includes searches of MEDLINE for systematic reviews) to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials.

Where necessary, we contacted authors of key papers and abstracts to request additional information about their trials.

We did not perform a separate search for adverse effects of interventions used for the treatment of hypertension. We considered adverse effects described in included studies only.

We also screened the reference lists of 41 potentially eligible studies and 25 relevant reviews and guidelines ([Balamuthusamy 2009](#CD002003-bbs2-0043){ref-type="ref-list"}; [Bangalore 2007](#CD002003-bbs2-0045){ref-type="ref-list"}; [Bangalore 2008](#CD002003-bbs2-0046){ref-type="ref-list"}; [Bath 2014](#CD002003-bbs2-0047){ref-type="ref-list"}; [Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}; [Chen 2010](#CD002003-bbs2-0051){ref-type="ref-list"}; [Dahlöf 2007](#CD002003-bbs2-0053){ref-type="ref-list"}; [ESH‐ESC 2013](#CD002003-bbs2-0055){ref-type="ref-list"}; [Gradman 2010](#CD002003-bbs2-0058){ref-type="ref-list"}; [Howlett 2014](#CD002003-bbs2-0062){ref-type="ref-list"}; [James 2014](#CD002003-bbs2-0063){ref-type="ref-list"}; [Jennings 2013](#CD002003-bbs2-0064){ref-type="ref-list"}; [Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}; [Kuyper 2014](#CD002003-bbs2-0069){ref-type="ref-list"}; [Larochelle 2014](#CD002003-bbs2-0070){ref-type="ref-list"}; [NICE 2006](#CD002003-bbs2-0078){ref-type="ref-list"}; [Poirier 2014](#CD002003-bbs2-0086){ref-type="ref-list"}; [Pucci 2016](#CD002003-bbs2-0089){ref-type="ref-list"}; [Ripley 2014](#CD002003-bbs2-0091){ref-type="ref-list"}; [Sander 2011](#CD002003-bbs2-0092){ref-type="ref-list"}; [Sciarretta 2011](#CD002003-bbs2-0093){ref-type="ref-list"}; [Thomopoulos 2015](#CD002003-bbs2-0096){ref-type="ref-list"}; [Wong 2014a](#CD002003-bbs2-0102){ref-type="ref-list"}; [Wong 2014b](#CD002003-bbs2-0103){ref-type="ref-list"}; [Wright 2009](#CD002003-bbs2-0106){ref-type="ref-list"}). In addition, we searched the World Health Organization International Clinical Trials Registry Platform ([www.who.int/trialsearch](www.who.int/trialsearch)) using the terms (beta‐blocker OR beta‐blockers) AND hypertension on 06 July 2015.

Data collection and analysis {#CD002003-sec2-0007}
----------------------------

For the current update, two review authors (CSW and HB) independently examined the eligibility of all titles and abstracts of studies identified by electronic or bibliographic scanning. The two review authors then independently assessed the risk of bias within included studies and extracted data. At each stage, the they resolved differences by discussion and consensus. If any discrepancies had persisted, JV would have arbitrated.

We assessed the risk of bias by addressing seven specific domains, as described in Chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#CD002003-bbs2-0061){ref-type="ref-list"}). The seven domains were random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other bias\'. For each included study, we described what the study authors reported that they did for each domain and then made a decision relating to the risk of bias for that domain; by assigning a judgement of \'low risk\' of bias, \'high risk\' of bias, or \'unclear risk\' of bias.

The data extracted for each study were: methods, including means of assigning participants to trial interventions, blinding of those receiving and providing care and outcome assessors, losses to follow‐up and how they were handled, and length of trial follow‐up; participant characteristics, including gender, ethnicity and comorbid conditions; interventions, including type and dose of beta‐blocker and other medications used; outcome measures, including morbidity and mortality endpoints, and adverse events.

We conducted quantitative analyses according to standard Cochrane guidelines ([Higgins 2011](#CD002003-bbs2-0061){ref-type="ref-list"}). We analysed trial participants in groups to which they were randomised, regardless of which or how much treatment they actually received, and expressed study results as risk ratios (RR) with 95% confidence intervals (CI). We assessed heterogeneity between studies by graphical inspection of results and, more formally followed by, the Chi^2^ test of homogeneity. In the absence of significant statistical heterogeneity between studies (P \> 0.1), we performed meta‐analysis using a fixed‐effect method ([Breslow 1980](#CD002003-bbs2-0048){ref-type="ref-list"}; [Mantel 1959](#CD002003-bbs2-0072){ref-type="ref-list"}). When there was significant heterogeneity between study results, we used the random‐effects method ([DerSimonian 1986](#CD002003-bbs2-0054){ref-type="ref-list"}), and investigated the cause of heterogeneity by stratified analysis with reference to the characteristics of the studies included in the meta‐analysis. The study characteristics considered in the subgroup analyses were age (less than 65 years versus 65 years and older), type of beta‐blockade (cardioselective versus non‐selective), control group (placebo versus no treatment), and risk of bias (high versus low risk of bias). In addition, we used the I^2^ statistic to describe the percentage of between‐study variability in effect estimates (for each outcome) attributable to true heterogeneity rather than chance ([Higgins 2003](#CD002003-bbs2-0060){ref-type="ref-list"}).

Various related reviews differ from ours in their inclusion or exclusion of various studies ([Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}; [Dahlöf 2007](#CD002003-bbs2-0053){ref-type="ref-list"}; [Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}; [Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}; [Wright 2009](#CD002003-bbs2-0106){ref-type="ref-list"}). We conducted sensitivity analyses to confirm that those different decisions did not lead to different conclusions.

Results {#CD002003-sec1-0005}
=======

Description of studies {#CD002003-sec2-0008}
----------------------

[Figure 1](#CD002003-fig-0001){ref-type="fig"} shows the search and selection of studies for this review, in line with the statement of preferred reporting items for systematic reviews and meta‐analyses ([Moher 2009](#CD002003-bbs2-0076){ref-type="ref-list"}).

![PRISMA flow diagram showing the search and selection of studies.](nCD002003-AFig-FIG01){#CD002003-fig-0001}

### Results of the search {#CD002003-sec3-0007}

We obtained 4453 records from the search conducted in January 2015; including 696 duplicates. Of the remaining 3757 records, 1263 were new records. We screened these and found no potentially eligible studies. The search conducted on 6 July 2015 found 450 studies in Clinicaltrials.gov and 283 records of 257 studies in the WHO International Clinical Trials Registry Platform. None of these \'ongoing\' studies was potentially eligible. Finally, the search conducted in June 2016 yielded 2716 records, with 596 being duplicates. We screened the remaining 2120 records (of which 1551 were new records) and found no potentially eligible studies.

From the search conducted in June 2006, we identified 21 potentially eligible RCTs ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}; [Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}; [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}; [CAPP 1999](#CD002003-bbs2-0017){ref-type="ref-list"}; [CONVINCE 1998](#CD002003-bbs2-0023){ref-type="ref-list"}; [Dutch TIA 1993](#CD002003-bbs2-0028){ref-type="ref-list"}; [MAPHY 1988](#CD002003-bbs2-0031){ref-type="ref-list"}; [NORDIL 2000](#CD002003-bbs2-0035){ref-type="ref-list"}; [STOP 1991](#CD002003-bbs2-0039){ref-type="ref-list"}; [STOP‐2 1999](#CD002003-bbs2-0040){ref-type="ref-list"}; [TEST 1995](#CD002003-bbs2-0041){ref-type="ref-list"}), from which we excluded eight. In five of the six RCTs, participants in the \'beta‐blocker\' group were not randomly allocated to a beta‐blocker at baseline but to conventional therapy, which referred to either a beta‐blocker or a diuretic ([CAPP 1999](#CD002003-bbs2-0017){ref-type="ref-list"}; [CONVINCE 1998](#CD002003-bbs2-0023){ref-type="ref-list"}; [NORDIL 2000](#CD002003-bbs2-0035){ref-type="ref-list"}; [STOP 1991](#CD002003-bbs2-0039){ref-type="ref-list"}; [STOP‐2 1999](#CD002003-bbs2-0040){ref-type="ref-list"}). None of the five RCTs reported data separately for the participants taking beta‐blockers and participants taking diuretics. We excluded two studies because not all participants had hypertension at baseline ([Dutch TIA 1993](#CD002003-bbs2-0028){ref-type="ref-list"}; [TEST 1995](#CD002003-bbs2-0041){ref-type="ref-list"}). We excluded the eighth RCT (MAPHY 1988), because it was a subset of an included RCT ([HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}).

The remaining 13 RCTs with 91,561 participants meet our inclusion criteria ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}; [Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}; [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}), and we included them in the previous review ([Bradley 2006](#CD002003-bbs2-0108){ref-type="ref-list"}; [Wiysonge 2007b](#CD002003-bbs2-0109){ref-type="ref-list"}).

The May 2011 search yielded 1566 records from the electronic databases (after removing duplicates), which we screened and identified 19 potentially eligible studies ([ACCORD 2010](#CD002003-bbs2-0014){ref-type="ref-list"}; [ADaPT 2008](#CD002003-bbs2-0015){ref-type="ref-list"}; [APSIS 2006](#CD002003-bbs2-0016){ref-type="ref-list"}; [CAPRICORN 2001](#CD002003-bbs2-0018){ref-type="ref-list"}; [CARDHIAC 2008](#CD002003-bbs2-0019){ref-type="ref-list"}; [CHHIPS 2009](#CD002003-bbs2-0020){ref-type="ref-list"}; [CIBIS‐II 1999](#CD002003-bbs2-0021){ref-type="ref-list"}; [COMET 2003](#CD002003-bbs2-0022){ref-type="ref-list"}; [COPE 2005](#CD002003-bbs2-0024){ref-type="ref-list"}; [COPERNICUS 2004](#CD002003-bbs2-0025){ref-type="ref-list"}; [COSMOS 2010](#CD002003-bbs2-0026){ref-type="ref-list"}; [Dietz 2008](#CD002003-bbs2-0027){ref-type="ref-list"}; [GEMINI 2008](#CD002003-bbs2-0029){ref-type="ref-list"}; [IMPACT‐HF 2004](#CD002003-bbs2-0030){ref-type="ref-list"}; [MERIT‐HF 2002](#CD002003-bbs2-0033){ref-type="ref-list"}; [Nilsson 2007](#CD002003-bbs2-0034){ref-type="ref-list"}; [REASON 2009](#CD002003-bbs2-0036){ref-type="ref-list"}; [RESOLVD 2000](#CD002003-bbs2-0037){ref-type="ref-list"}; [SENIORS 2005](#CD002003-bbs2-0038){ref-type="ref-list"}). Following review of the full‐text articles of the 19 studies, we found that none of them met our inclusion criteria.

Finally, we obtained 508 abstracts from the December 2011 search; with one potentially eligible study ([Marazzi 2011](#CD002003-bbs2-0032){ref-type="ref-list"}). This study did not met our inclusion criteria and was excluded.

### Included studies {#CD002003-sec3-0008}

The 13 included RCTs compared a beta‐blocker to a placebo or no treatment ([Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}), a diuretic ([Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}), a CCB ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}), an ACE inhibitor ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}), or an ARB ([LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}).

Unlike two related reviews ([Dahlöf 2007](#CD002003-bbs2-0053){ref-type="ref-list"}; [Wright 2009](#CD002003-bbs2-0106){ref-type="ref-list"}), we did not consider the [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"} as a placebo‐controlled trial because participants in the \'less tight control group\' (which these reviews consider as placebo) took antihypertensive treatment for 57% of total person‐years.

Ten RCTs recruited participants of both sexes ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}; [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}). Six RCTs included participants up to the age of 65 years ([Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}), and the rest included participants aged 18 to 70 years ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}), 40 to 79 years ([ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}), 45 to 75 years ([ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}), more than 50 years ([INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}), 55 to 80 years ([LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}), 60 to 79 years ([Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}), and 65 to 74 years ([MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}).

All 13 studies were conducted in industrialised countries, mainly Western Europe and North America. Nine RCTs provided information on race or ethnicity: [AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"} (0% white), [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"} (44% white), [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"} (48% white), [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"} (86% white), [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"} (92% white), [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"} (92% white), [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"} (95.0% white), [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"} (98.2% white), and [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"} (more than 99% white).

We have described the 13 RCTs included in this review in detail in the [Characteristics of included studies](#CD002003-sec2-0020){ref-type="sec"} table, and summarised their main features below:

[AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}. This RCT compared the effects of an ACE inhibitor (ramipril), a CCB (amlodipine), and a beta‐blocker (metoprolol) on hypertensive renal disease progression in African American people aged 18 to 70 years. Additional antihypertensive agents were added sequentially to achieve blood pressure goals. Cardiovascular events, cardiovascular mortality. and all‐cause mortality were reported. The trial followed 1094 participants for a mean duration of 4.1 years.[ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}. The participants were randomised to a CCB (amlodipine) adding an ACE inhibitor (perindopril) as required to reach blood pressure targets or a beta‐blocker (atenolol) adding a diuretic (bendroflumethiazide) as required. The participants were men and women with hypertension aged 40 to 79 years. The main outcome measure was combined non‐fatal myocardial infarction and fatal CHD, and secondary endpoints included all‐cause mortality, cardiovascular mortality, and total stroke. At the end of the trial, 78% of participants were taking at least two antihypertensive medications and only 15% were taking amlodipine and 9% were taking atenolol monotherapy. The study enrolled 19,257 participants and followed them for a median duration of 5.5 years.[Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}. This RCT evaluated the long‐term effects of a thiazide diuretic (bendroflumethiazide) compared to a beta‐blocker (propranolol) in men with hypertension aged 47 to 54 years. Hydralazine and other antihypertensive medications were added to achieve blood pressure goals. The investigators reported total mortality. At the end of the trial, 70% of participants taking diuretic and 74% taking beta‐blockers were on assigned treatment and 40% of participants taking diuretic and 42% taking beta‐blocker were on monotherapy. The study enrolled 106 participants and the study lasted 10 years.[Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}. The trial was designed to determine whether the treatment of hypertension using beta‐blocker therapy (atenolol) in a stepped‐care approach compared to no treatment reduced the incidence of stroke, CHD, cardiovascular death, or all‐cause mortality. Step one was monotherapy with atenolol, step two added a thiazide diuretic (bendrofluazide), and steps three and four added other antihypertensive agents. At the end of the trial, 70% of participants in the beta‐blocker group were taking assigned treatment, 17% were taking atenolol alone, and 53% were taking atenolol plus bendrofluazide. The trial followed up 884 participants aged 60 to 79 years for a mean duration of 4.4 years.[ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}. The trial was designed to compare the effects of a beta‐blocker (atenolol) and a CCB (lacidipine) on the change in mean maximum intima‐media thickness and plaque number in men and women with hypertension. The investigators also reported data on fatal and non‐fatal cardiovascular events and total mortality. If satisfactory blood pressure control was not achieved, trial medication could be increased, and when necessary open‐label hydrochlorothiazide was added. At the end of the trial, 85% of participants in the beta‐blocker group and 78% in the CCB group were known to be on assigned treatment. The participants on monotherapy at the end of the trial were 43% in the beta‐blocker group and 42% in the CCB group. The trial followed up 2334 participants aged 45 to 75 years for a mean duration of 3.75 years.[HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}. The trial was designed to compare the effects of beta‐blockers (mainly atenolol, 1599 participants or metoprolol, 1631 participants) and thiazide diuretics (bendroflumethiazide or hydrochlorothiazide) on the incidence of non‐fatal myocardial infarction, CHD mortality, and total mortality in men with mild to moderate hypertension. Other drugs were added to reduce blood pressure as necessary. At the end of the trial, 86% of participants in the beta‐blocker group and 83% in the diuretic group were on assigned treatment. More participants in the beta‐blocker group (68%) than in the diuretic group (62%) were on monotherapy. The trial followed up 6569 participants aged 40 to 64 years for a mean duration of 45.1 months.[INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}. The trial was designed to compare the effect of a CCB (verapamil sustained release, SR), and a beta‐blocker (atenolol) in hypertensive participants with documented coronary artery disease, on all‐cause and cardiovascular death, and various non‐fatal cardiovascular events. Other drugs, mainly trandolapril (to the verapamil SR group) and hydrochlorothiazide (to the atenolol group), were added to achieve blood pressure control as required. At two years, 77.5% of participants in the beta‐blocker group and 81.5% in the CCB group were on the assigned treatment (18.1% taking beta‐blocker and 17.4% taking CCB monotherapy). The trial followed up 22,576 participants aged 50 years and older for a mean duration of 2.7 years.[IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}. The trial was designed to evaluate the effect of antihypertensive therapy with a beta‐blocker (oxprenolol) on the incidence of cardiac events (myocardial infarction and sudden death) and cerebrovascular accidents. Trial medication could be increased or other non‐beta‐blocker antihypertensive drugs added according to predefined recommendations, as necessary, to reduce blood pressure. During the trial, 30% of participants remained on beta‐blocker monotherapy while 15% remained on placebo only. The trial followed up 6357 participants aged 40 to 64 years for three to five years.[LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}. The trial was designed to evaluate the effects of an ARB (losartan) compared to a beta‐blocker (atenolol) in people with hypertension with documented left ventricular hypertrophy on the combined incidence of cardiovascular mortality and morbidity. Other drugs were added to reduce blood pressure as necessary. At the end of the trial, 63% of participants in the beta‐blocker group and 67% in the ARB group were on assigned treatment; 11% of participants were on monotherapy in each group. The trial followed up 9193 participants aged 55 to 80 years for a mean duration of 4.8 years.[MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}. The trial was designed to determine whether drug treatment of mild hypertension reduced the rates of fatal and non‐fatal stroke and of coronary events. Participants were randomised to active treatment (propranolol or bendrofluazide) or placebo. At the end of the study, the proportion of participants on assigned treatment in the beta‐blocker group was 59%, in the diuretic group was 62%, and placebo group was 56%. The trial followed up 17,354 participants aged 35 to 64 years for a mean duration of 4.9 years.[MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}. The trial was designed to establish whether treatment of hypertension in older adults reduced the risk of stroke, CHD, and death from all causes. Participants were randomised to a beta‐blocker (atenolol), a diuretic (amiloride and hydrochlorothiazide), or placebo. Other drugs were added as necessary. At five years, 52% of participants assigned to beta‐blockers required supplementary drugs compared to 38% in the diuretic group. At the end of the study, 37% of participants in the beta‐blocker group, 52% in the diuretic group, and 47% in the placebo group were on the assigned treatment. The trial followed up 4396 participants aged 65 to 74 years for 5.8 years.[UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}. The trial was designed to determine whether tight control of blood pressure with either a beta‐blocker (atenolol) or an ACE inhibitor (captopril) prevents macrovascular and microvascular complications in participants with type 2 diabetes. Participants were randomised to study drugs, with other drugs added as required. At the end of the trial, 65% of participants in the beta‐blocker group and 78% in the ACE inhibitor group were on assigned treatment. The trial followed up 758 participants aged 25 to 65 years for 8.4 years.[VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}. This trial compared a beta‐blocker (propranolol) and a diuretic (hydrochlorothiazide) for the initial treatment of hypertension in men aged 21 to 65 years. During treatment, fewer participants receiving hydrochlorothiazide required termination as compared with men receiving propranolol. A total of 683 men were recruited. During the initial 10 weeks (i.e. dose‐finding period), the clinic staff titrated the blinded drug upward until the target blood pressure was reached. Participants were withdrawn from the study if, on any follow‐up visit, diastolic blood pressure was 120 mmHg or more. The trial lasted one year.

### Excluded studies {#CD002003-sec3-0009}

We excluded 28 potentially eligible studies because of the very short duration of relevant interventions ([CHHIPS 2009](#CD002003-bbs2-0020){ref-type="ref-list"}; [Dietz 2008](#CD002003-bbs2-0027){ref-type="ref-list"}), a beta‐blocker was not given as monotherapy or first‐line therapy ([ACCORD 2010](#CD002003-bbs2-0014){ref-type="ref-list"}; [CAPP 1999](#CD002003-bbs2-0017){ref-type="ref-list"}; [CAPRICORN 2001](#CD002003-bbs2-0018){ref-type="ref-list"}; [CARDHIAC 2008](#CD002003-bbs2-0019){ref-type="ref-list"}; [CIBIS‐II 1999](#CD002003-bbs2-0021){ref-type="ref-list"}; [CONVINCE 1998](#CD002003-bbs2-0023){ref-type="ref-list"}; [COPE 2005](#CD002003-bbs2-0024){ref-type="ref-list"}; [GEMINI 2008](#CD002003-bbs2-0029){ref-type="ref-list"}; [Marazzi 2011](#CD002003-bbs2-0032){ref-type="ref-list"}; [NORDIL 2000](#CD002003-bbs2-0035){ref-type="ref-list"}; [STOP 1991](#CD002003-bbs2-0039){ref-type="ref-list"}; [STOP‐2 1999](#CD002003-bbs2-0040){ref-type="ref-list"}), the study was not an RCT ([ADaPT 2008](#CD002003-bbs2-0015){ref-type="ref-list"}), the study was a subset of an included RCT ([MAPHY 1988](#CD002003-bbs2-0031){ref-type="ref-list"}), the study has not reported data on mortality or hard cardiovascular endpoints ([COSMOS 2010](#CD002003-bbs2-0026){ref-type="ref-list"}; [Nilsson 2007](#CD002003-bbs2-0034){ref-type="ref-list"}), or not all enrolled participants had hypertension ([APSIS 2006](#CD002003-bbs2-0016){ref-type="ref-list"}; [CIBIS‐II 1999](#CD002003-bbs2-0021){ref-type="ref-list"}; [CAPRICORN 2001](#CD002003-bbs2-0018){ref-type="ref-list"}; [COMET 2003](#CD002003-bbs2-0022){ref-type="ref-list"}; [COPERNICUS 2004](#CD002003-bbs2-0025){ref-type="ref-list"}; [Dutch TIA 1993](#CD002003-bbs2-0028){ref-type="ref-list"}; [IMPACT‐HF 2004](#CD002003-bbs2-0030){ref-type="ref-list"}; [MERIT‐HF 2002](#CD002003-bbs2-0033){ref-type="ref-list"}; [RESOLVD 2000](#CD002003-bbs2-0037){ref-type="ref-list"}; [SENIORS 2005](#CD002003-bbs2-0038){ref-type="ref-list"}; [TEST 1995](#CD002003-bbs2-0041){ref-type="ref-list"}).The trials where not all enrolled participants had hypertension were of beta‐blockers in people with heart failure ([CIBIS‐II 1999](#CD002003-bbs2-0021){ref-type="ref-list"}; [COMET 2003](#CD002003-bbs2-0022){ref-type="ref-list"}; [COPERNICUS 2004](#CD002003-bbs2-0025){ref-type="ref-list"}; [IMPACT‐HF 2004](#CD002003-bbs2-0030){ref-type="ref-list"}; [Marazzi 2011](#CD002003-bbs2-0032){ref-type="ref-list"}; [MERIT‐HF 2002](#CD002003-bbs2-0033){ref-type="ref-list"}; [RESOLVD 2000](#CD002003-bbs2-0037){ref-type="ref-list"}; [SENIORS 2005](#CD002003-bbs2-0038){ref-type="ref-list"}), angina pectoris ([APSIS 2006](#CD002003-bbs2-0016){ref-type="ref-list"}), post‐myocardial infarction ([CAPRICORN 2001](#CD002003-bbs2-0018){ref-type="ref-list"}), or transient ischaemic attack or stroke ([Dutch TIA 1993](#CD002003-bbs2-0028){ref-type="ref-list"}; [TEST 1995](#CD002003-bbs2-0041){ref-type="ref-list"}).

We have described each of the 28 excluded studies in greater detail in the [Characteristics of excluded studies](#CD002003-sec2-0021){ref-type="sec"} table.

Risk of bias in included studies {#CD002003-sec2-0009}
--------------------------------

The risk of bias in included studies is summarised in [Figure 2](#CD002003-fig-0002){ref-type="fig"} and [Figure 3](#CD002003-fig-0003){ref-type="fig"}.

![Risk of bias graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies.](nCD002003-AFig-FIG02){#CD002003-fig-0002}

![Risk of bias summary: review authors\' judgements about each risk of bias item for each included study.](nCD002003-AFig-FIG03){#CD002003-fig-0003}

### Allocation {#CD002003-sec3-0010}

Seven trials reported the method used to generate the randomisation sequence adequately ([ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}; [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}). It was unclear in the remaining six ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}).

Five trials had adequate allocation concealment ([ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}; [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}; [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}), while in the remaining eight, the information provided was insufficient to assess this aspect of risk of bias ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}; [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}).

### Blinding {#CD002003-sec3-0011}

Outcome assessors were blinded in 11 studies ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}; [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}; [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}), and two trials were completely unblinded ([Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}). However, in the [Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"} study, the outcome assessed (i.e. death) is unlikely to be influenced by lack of blinding.

Participants were also blinded in seven trials ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}), but healthcare workers were only blinded in five trials ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}) .

### Incomplete outcome data {#CD002003-sec3-0012}

Loss to follow‐up was negligible in [AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"} (0%), [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"} (0.3%), [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"} (0.6%), [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"} (1%), [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"} (2%), [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"} (2.5%), [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"} (4%), [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"} (4%), [Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"} (7%), and [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"} (8%), but high in [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"} (19%) and [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"} (25%) trials. [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"} did not report loss to follow‐up.

The following trials stated the proportions of participants taking assigned beta‐blocker treatment at the end of the trial: [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"} (86%), [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"} (85%), [Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"} (74%), [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"} (70%), [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"} (65%), [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"} (63%), [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"} (59%), [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"} (39%), [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"} (37%), and [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"} (30%).

### Selective reporting {#CD002003-sec3-0013}

Ten studies reported outcomes as stated in the respective study protocols ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}; [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}; [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}; [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}). We did not have access to the study protocols of the remaining studies ([Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}).

### Other potential sources of bias {#CD002003-sec3-0014}

All the studies added other antihypertensive drugs to the first‐line treatment to help achieve the blood pressure goals. The observed effects may equally have resulted from the additional drugs used. In addition, two studies were stopped early for data‐dependent reasons ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}).

The high risk of bias in most of the included studies limits our confidence in the effect estimates for beta‐blockers as first‐line therapy for hypertension ([Balshem 2011](#CD002003-bbs2-0044){ref-type="ref-list"}; [Guyatt 2011](#CD002003-bbs2-0059){ref-type="ref-list"}), as shown in the \'Summary of findings\' tables ([Table 1](#CD002003-tbl-0001){ref-type="table"}; [Table 2](#CD002003-tbl-0002){ref-type="table"}; [Table 3](#CD002003-tbl-0003){ref-type="table"}; [Table 4](#CD002003-tbl-0004){ref-type="table"}).

Effects of interventions {#CD002003-sec2-0010}
------------------------

See: [Table 1](#CD002003-tbl-0001){ref-type="table"}; [Table 2](#CD002003-tbl-0002){ref-type="table"}; [Table 3](#CD002003-tbl-0003){ref-type="table"}; [Table 4](#CD002003-tbl-0004){ref-type="table"}

Due to the small number of participants in trials with ACE inhibitors (2 trials with 1635 participants ([AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"})) and ARBs (1 trial with 9193 participants ([LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"})), we combined data for the two classes of RAS inhibitors. We excluded the trial that compared the effects of atenolol and aliskiren, the first DRI to be approved for the treatment of hypertension ([Dietz 2008](#CD002003-bbs2-0027){ref-type="ref-list"}), because of the very short duration (12 weeks) of relevant interventions.

### Mortality {#CD002003-sec3-0015}

The effect of beta‐blocker therapy on total mortality was not significantly different from that of placebo (4 trials, 23,613 participants: RR 0.99, 95% CI 0.88 to 1.11; I^2^ = 0%; *moderate certainty evidence*).

Apart from the four studies included in our placebo comparison, previous related reviews included four other studies ([Dutch TIA 1993](#CD002003-bbs2-0028){ref-type="ref-list"}; [STOP 1991](#CD002003-bbs2-0039){ref-type="ref-list"}; [TEST 1995](#CD002003-bbs2-0041){ref-type="ref-list"}; [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}). When we added these studies in a sensitivity analysis, there was still no evidence of a significant effect of beta‐blockers on mortality (8 trials, 28,181 participants: RR 0.93, 95% CI 0.85 to 1.02, I^2^ = 39%).

In addition, total mortality was not significantly different between beta‐blockers and diuretics (5 trials, 18,241 participants: RR 1.04, 95% CI 0.91 to 1.19, I^2^ = 0%; *moderate certainty evidence*), and beta‐blockers and RAS inhibitors (3 trials, 10,828 participants: RR 1.10, 95% CI 0.98 to 1.24, I^2^ = 54%; *moderate certainty evidence*).

Total mortality was significantly higher for beta‐blockers compared to CCBs (4 trials, 44,825 participants: RR 1.07, 95% CI 1.00 to 1.14, I^2^ = 2%; *moderate certainty evidence*) corresponding to an absolute risk increase (ARI) of 0.5% and number of participants needed to treat for an additional harmful outcome (NNTH) with a beta‐blocker rather than a CCB treated for five years of 200.

### Total stroke {#CD002003-sec3-0016}

Participants treated with a beta‐blocker had a significantly lower risk of developing a stroke than participants taking placebo (4 trials, 23,613 participants: RR 0.80, 95% CI 0.66 to 0.96, I^2^ = 0%; *low certainty evidence*). A sensitivity analysis adding the four studies included in related reviews yielded similar results (8 trials, 28,181 participants: RR 0.79, 95% CI 0.70 to 0.90, I^2^ = 31%).

Expressed as absolute risk reduction (ARR), beta‐blockers reduced the risk of stroke by 0.5% (compared to placebo). The corresponding number of participants needed to treat for an additional beneficial outcome (NNTB) with a beta‐blocker for approximately five years to prevent one stroke was 200.

We found no statistically significant difference in stroke events between participants treated with a beta‐blocker and participants treated with a diuretic (4 trials, 18,135 participants: RR (random effects) 1.17, 95% CI 0.65 to 2.09, I^2^ = 73%; *moderate certainty evidence*). However, participants treated with a beta‐blocker (atenolol) had more stroke events than participants treated with a CCB (3 trials, 44,167 participants: RR 1.24, 95% CI 1.11 to 1.40, I^2^ = 0%; ARI = 0.6%, NNTH 180; *moderate certainty evidence*) or an RAS inhibitor (2 trials, 9951 participants: RR 1.30, 95% CI 1.11 to 1.53, I^2^ = 29%; ARI = 1.5%, NNTH 65; *moderate certainty evidence*).

The heterogeneity among trials comparing beta‐blockers to diuretics may be related to the type of beta‐blockade (I^2^ = 73%, P = 0.01). There was an increase in the risk of stroke with the non‐selective beta‐blocker, propranolol, in the [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"} trial (RR 2.28, 95% CI 1.31 to 3.95) with an ARI of 0.5% and NNTH with a beta‐blocker for approximately five years of 200; but no difference with the cardio‐selective beta‐blockers, atenolol or metoprolol (RR 1.00, 95% CI 0.74 to 1.33, I^2^ = 60).

### Total coronary heart disease {#CD002003-sec3-0017}

The effect of beta‐blocker therapy on CHD was not significantly different from that of a placebo (4 trials, 23,613 participants: RR 0.93, 95% CI 0.81 to 1.07, I^2^ = 0%; *moderate certainty evidence*). A sensitivity analysis adding the four studies included in related reviews yielded similar results (8 trials, 28,181 participants: RR 0.91, 95% CI 0.81 to 1.02, I^2^ = 0%).

The beta‐blocker effect was similar to that of a diuretic (4 trials, 18,135 participants: RR (random effects) 1.12, 95% CI 0.82 to 1.54, I^2^ = 66%; *low certainty evidence*), a CCB (3 trials, 44,167 participants: RR 1.05, 95% CI 0.96 to 1.15, I^2^ = 32%; *moderate certainty evidence*), or a RAS inhibitor (2 trials, 9951 participants: RR 0.90, 95% CI 0.76 to 1.06, I^2^ = 42%; *low certainty evidence*).

There was significant statistical heterogeneity between trials comparing beta‐blockers to diuretics (I^2^ = 66%, P = 0.03), which may be explained by differences in age. The pooled RR in the trials whose participants were less than 65 years of age was 0.97 (95% CI 0.81 to 1.17, I^2^ = 5%, P = 0.35), while in the single trial involving participants aged 65 years and older atenolol was associated with an increased CHD incidence (RR 1.63, 95% CI 1.15 to 2.32) ([MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}). The difference between the subgroups was statistically significant (test for subgroup differences: Chi^2^ = 6.70, degrees of freedom (df) = 1, P = 0.01, I^2^ = 85.1%).

### Total cardiovascular disease {#CD002003-sec3-0018}

Compared to participants taking placebo, participants taking beta‐blockers had a significantly reduced risk of having a cardiovascular event (4 trials, 23,613 participants: RR 0.88, 95% CI 0.79 to 0.97, I^2^ = 21%; ARR 0.7%, NNTB 140 for 5 years; *low certainty evidence*). A sensitivity analysis adding studies included in related reviews yielded similar results.

The effect of beta‐blockers on total cardiovascular events was not significantly different from that of diuretics (4 trials, 18,135 participants: RR 1.13, 95% CI 0.99 to 1.28, I^2^ = 45%; *moderate certainty evidence*) and RAS inhibitors (3 trials, 10,828 participants: RR (random effects) 1.00, 95% CI 0.72 to 1.38, I^2^ = 74%; *low certainty evidence*). Beta‐blockers increased total cardiovascular disease as compared to CCBs (2 trials, 19,915 participants: RR 1.18, 95% CI 1.08 to 1.29, I^2^ = 0%; ARI = 1.3%, NNTH 80; *moderate certainty evidence*).

The significant heterogeneity of effect on total cardiovascular disease between beta‐blockers and RAS inhibitors (I^2^ = 74%, P = 0.02) was explained by the effect of beta‐blockers being similar to that of ACE inhibitors (2 trials, 635 participants: RR 0.82, 95% CI 0.64 to 1.05, I^2^ = 0%) but worse than that of an ARB (1 trial, 9193 participants: RR 1.16, 95% CI 1.04 to 1.30) with an ARI of 1.8% and NNTH of 56.

### Adverse events leading to discontinuation of allocated treatment {#CD002003-sec3-0019}

We analysed data on the rate of withdrawal from randomly assigned treatment due to any adverse events, and also report on the frequency of specific adverse events including depression, fatigue, and sexual dysfunction.

Trial participants on a beta‐blocker were no more likely than participants receiving a placebo to discontinue treatment due to adverse events (3 trials, 22,729 participants: RR (random effects) 3.38, 95% CI 0.82 to 13.95; *low certainty evidence*). However, there was significant heterogeneity of effect between the trials (I^2^ = 100%, P \< 0.00001); with no difference in the likelihood of discontinuing treatment with oxprenolol (1 trial, 6357 participants: RR 0.95, 95% CI 0.87 to 1.04) and an increased likelihood with propranolol or atenolol (2 trials, 16,372; RR (random effects) 6.35, 95% CI 3.94 to 10.22, I^2^ = 91%). A sensitivity analysis adding studies included in related reviews also revealed significant heterogeneity of effect (I^2^ = 99%, P \< 0.00001).

Participants taking a beta‐blocker were more likely to discontinue treatment due to adverse events than participants taking a RAS inhibitor (2 trials, 9951 participants: RR 1.41, 95% CI 1.29 to 1.54, I^2^ = 12%; ARI 5.5%, NNTH 18; *low certainty evidence*), but there was no significant difference with a diuretic (3 trials, 11,566 participants: RR (random effects) 1.69, 95% CI 0.95 to 3.00, I^2^ = 95%; *low certainty evidence*) or a CCB (2 trials, 21,591 participants: RR (random effects) 1.20, 95% CI 0.71 to 2.04, I^2^ = 93%; *low certainty evidence*).

There was no significant difference in the incidence of depressive symptoms between beta‐blockers and placebo (2 trials, 7082 participants: RR (random effects) 1.03, 95% CI 0.65 to 1.63, I^2^ = 83.0) or RAS inhibitors (1 trial, 758 participants: RR 1.12, 95% CI 0.07 to 17.80).

Beta‐blockers did not increase the risk of fatigue compared to placebo or no treatment (2 trials, 13,782 participants: RR (random effects) 4.35, 95% CI 0.17 to 108.74, I^2^ = 99.0%). However, trial participants taking a beta‐blocker were more likely to develop fatigue than participants taking a diuretic (1 trial, 8700 participants: RR 2.48, 95% CI 1.73 to 3.54), a CCB (1 trial, 19,257 participants: RR 1.99, 95% CI 1.84 to 2.16), or a RAS inhibitor (2 trials, 9951 participants: RR 1.17, 95% CI 1.06 to 1.28, I^2^ = 0%).

The risk of sexual dysfunction was not different between beta‐blockers and placebo (2 trials, 19,414 participants: RR (random effects) 1.95, 95% CI 0.33 to 11.59, I^2^ = 97.5%). However, beta‐blockers decreased the risk of sexual dysfunction when compared to diuretics (1 trial, 8700 participants: RR 0.50, 95% CI 0.36 to 0.70); but increased the risk relative to CCBs (1 trial, 19,257 participants: RR 1.27, 95% CI 1.14 to 1.42) and RAS inhibitors (2 trials, 9951 participants: RR 1.34, 95% CI 1.10 to 1.63, I^2^ = 56.2%).

### Degree of reduction in systolic and diastolic blood pressure achieved by beta‐blocker therapy in relation to each comparator treatment {#CD002003-sec3-0020}

Compared to placebo, first‐line beta‐blockers plus supplementary antihypertensive drugs reduced systolic blood pressure by about 11 mmHg and diastolic blood pressures by about 6 mmHg ([Table 10](#CD002003-tbl-0010){ref-type="table"}). However, compared to diuretics, CCBs, or RAS inhibitors, the mean systolic and diastolic blood pressures at the end of the trials were 0 to 2 mmHg higher in the beta‐blocker group ([Table 10](#CD002003-tbl-0010){ref-type="table"}).

###### Effect of beta‐blockers on lowering of blood pressure

  ----------------------------------------------------------- --------------------------------------- ---------------------------------------------------- --------------------------------- ------------------------------------
  **Trial identification**                                    **Beta‐blocker**                        **Comparison drug**                                  **Baseline BP (SBP/DBP; mmHg)**   **Mean BP difference (SBP/DBP)\***
  Beta‐blocker vs placebo/no treatment                                                                                                                                                       
  [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}      Atenolol                                No treatment                                         196.7/99.7                        ‐18.0/‐11.0
  [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}      Atenolol                                Placebo                                              184.0/91.0                        ‐13.0/‐7.0
  [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}        Propranolol                             Placebo                                              162.0/98.5                        ‐9.5/‐5.0
  [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}     Oxprenolol                              Placebo                                              173.2/107.9                       ‐4.1/‐1.5
  Beta‐blocker vs diuretic                                                                                                                                                                   
  [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}      Atenolol                                Diuretic                                             184.0/91.0                        +1.0/‐0.5
  [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}     Atenolol or metoprolol or propranolol   Diuretic                                             166.0/107.9                       0.0/‐1.0
  [Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}   Propranolol                             Diuretic                                             174.0/105.5                       ‐4.0/+2.0
  [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}    Propranolol                             Diuretic                                             146.3/101.5                       +7.0/+1.6
  [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}        Propranolol                             Diuretic                                             162.0/98.5                        +3.5/+1.0
  Beta‐blocker vs calcium‐channel blocker                                                                                                                                                    
  [ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}       Atenolol                                Calcium‐channel blocker                              163.1/101.3                       +0.2/‐0.1
  [INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}     Atenolol                                Calcium‐channel blocker                              150.8/87.2                        +0.3/+0.2
  [ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}      Atenolol                                Calcium‐channel blocker                              164.0/94.7                        +1.6/+1.8
  [AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}       Metoprolol                              Calcium‐channel blocker                              150.0/96.0                        +2.0/0.0
  Beta‐blocker vs renin‐angiotensin system inhibitor                                                                                                                                         
  [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}   Atenolol                                Renin‐angiotensin system inhibitor (ACE inhibitor)   159.0/93.0                        ‐1.0/‐1.0
  [LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}       Atenolol                                Renin‐angiotensin system inhibitor (ARB)             174.5/97.7                        +1.1/‐0.2
  [AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}       Metoprolol                              Renin‐angiotensin system inhibitor (ACE inhibitor)   150.0/96.0                        0.0/‐1.0
  ----------------------------------------------------------- --------------------------------------- ---------------------------------------------------- --------------------------------- ------------------------------------

\* \'Minus sign\' means beta‐blocker group had lower BP, and \'plus sign\' means beta‐blocker group had higher BP than control group.

ACE: angiotensin‐converting enzyme; ARB: angiotensin receptor blocker; BP: blood pressure; DBP: diastolic blood pressure; SBP: systolic blood pressure.

Discussion {#CD002003-sec1-0006}
==========

Summary of main results {#CD002003-sec2-0011}
-----------------------

We included 13 eligible RCTs, which compared beta‐blockers to placebo, diuretics, CCBs, and RAS inhibitors. These RCTs generally had a high risk of bias resulting from limitations in study design, conduct, and data analysis.

We found little or no difference in all‐cause mortality between beta‐blockers and placebo, diuretics or RAS inhibitors, but all‐cause mortality was higher for beta‐blockers compared to CCBs. The evidence on mortality was of moderate‐certainty for all comparisons. Total cardiovascular disease was lower for beta‐blockers compared to placebo, which is a reflection of the significant decrease in stroke, since there was little or no difference in CHD between beta‐blockers and placebo. There were no significant differences between beta‐blockers and placebo in adverse events leading to withdrawal from assigned treatment (low‐certainty evidence).

The effect of beta‐blockers on cardiovascular disease was worse than that of CCBs (moderate‐certainty evidence), but was not different from that of diuretics (moderate‐certainty evidence) or RAS inhibitors (low‐certainty evidence). In addition, there was an increase in stroke with beta‐blockers compared to CCBs (moderate‐certainty evidence) and RAS inhibitors (moderate‐certainty evidence). However, there was little or no difference in CHD between beta‐blockers and diuretics (low‐certainty evidence), CCBs (moderate‐certainty evidence), or RAS inhibitors (low‐certainty evidence). Participants taking beta‐blockers were more likely to discontinue treatment due to adverse events than participants taking RAS inhibitors (moderate‐certainty evidence), but there was no significant difference with diuretics (low‐certainty evidence) or CCBs (low certainty evidence).

We demonstrated a high degree of homogeneity of effect for the comparisons of beta‐blockers versus CCBs for all‐cause mortality (I^2^ = 2%), stroke (I^2^ = 0%), and total cardiovascular events (I^2^ = 0%) but with less homogeneity for CHD (I^2^ = 32%). For the comparison of beta‐blockers versus RAS inhibitors, the I^2^ values for stroke and withdrawal rates also demonstrate a high degree of consistency across the studies making our conclusions more secure ([Higgins 2003](#CD002003-bbs2-0060){ref-type="ref-list"}; [Higgins 2011](#CD002003-bbs2-0061){ref-type="ref-list"}). For the comparison with diuretics, there were no statistically significant differences in any morbidity or mortality outcome.

Overall completeness and applicability of evidence {#CD002003-sec2-0012}
--------------------------------------------------

Though beta‐blockers are a heterogeneous group of pharmacological agents, differing in beta‐adrenergic receptor selectivity, intrinsic sympathomimetic activity, and vasodilatory capabilities ([Kamp 2010](#CD002003-bbs2-0067){ref-type="ref-list"}; [Pedersen 2007](#CD002003-bbs2-0084){ref-type="ref-list"}; [Polónia 2010](#CD002003-bbs2-0087){ref-type="ref-list"}), we found no outcome trials with head‐to‐head comparisons between beta‐blockers for the treatment of hypertension ([Poirier 2014](#CD002003-bbs2-0086){ref-type="ref-list"}). Of the 40,245 participants using beta‐blockers in this review, atenolol was used by 30,150 participants (75%). Due to the paucity of data using beta‐blockers other than atenolol, it is not possible to say whether the (lack of) effectiveness and (in)tolerability of beta‐blockers seen in this review is a property of atenolol or is a class effect of beta‐blockers. From this review, we cannot support the claim by Lindhom and colleagues that cardioselective beta‐blockers may be inferior to non‐selective beta‐blockers in the treatment of hypertension ([Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}).

A limitation of both previous reviews and ours is the absence of trials assessing the effects of the new vasodilating beta‐blockers (e.g. carvedilol, bucindolol, and nebivolol) on mortality and hard cardiovascular outcomes. Possible mechanisms to explain the poor ability of beta‐blockers to reduce stroke include a propensity to cause diabetes ([Opie 2004](#CD002003-bbs2-0081){ref-type="ref-list"}), a failure to decrease central aortic pressure as much as brachial pressure, and others. Diabetes likely requires years to develop cardiovascular complications ([Verdecchia 2004](#CD002003-bbs2-0097){ref-type="ref-list"}), so we favour the mechanism involving lesser reduction of central aortic pressure by beta‐blockers. Vasodilating beta‐blockers ([Broeders 2000](#CD002003-bbs2-0049){ref-type="ref-list"}; [Kalinowski 2003](#CD002003-bbs2-0066){ref-type="ref-list"}; [Pucci 2016](#CD002003-bbs2-0089){ref-type="ref-list"}) have been shown to reduce central pressures better than conventional beta‐blockers ([Kamp 2010](#CD002003-bbs2-0067){ref-type="ref-list"}; [Polónia 2010](#CD002003-bbs2-0087){ref-type="ref-list"}); most probably because vasodilatation favourably alters the pattern of the pressure wave reflecting back from the periphery, thereby lowering the central pressure. Nonetheless, carvedilol and nebivolol also cause bradycardia, which is thought to be the principal mechanism whereby atenolol with or without thiazide may be less able to lower the central pressure than amlodipine with or without perindopril ([Williams 2006](#CD002003-bbs2-0100){ref-type="ref-list"}). At any rate, high‐quality outcome studies are required to show that hard cardiovascular endpoints such as stroke and CHD are significantly reduced by beta‐blockers not studied in this review.

Information reported in the trials considered in this review was insufficient to explore the effect of race or ethnicity, as most trial participants were white ([Park 2007](#CD002003-bbs2-0083){ref-type="ref-list"}). However, the finding that beta‐blockers are less effective than diuretics in older people, is most likely to be applicable to older black people as well ([Materson 1993](#CD002003-bbs2-0073){ref-type="ref-list"}).

Quality of the evidence {#CD002003-sec2-0013}
-----------------------

The certainty of the evidence on the effects of beta‐blockers was generally moderate to low ([Balshem 2011](#CD002003-bbs2-0044){ref-type="ref-list"}). In the GRADE system, RCTs without important limitations constitute high‐certainty evidence. However, the system considers five factors that can lower the certainty of the evidence: study limitations, heterogeneity, indirectness, imprecision, and publication bias. Overall, the GRADE system classifies research evidence into high‐, moderate‐, low‐, or very low‐certainty. Low‐certainty evidence implies that the \"true effect is likely to be different from the estimate of effect\" found in the review.

Our major concern with the evidence related to inherent shortcomings in the included primary studies. The emphasis was often on the results with the first drug used, whereas most studies used stepped‐up therapy to help achieve the blood pressure goals. Thus poorer outcomes with first‐line beta‐blockers may equally have resulted from the use of other drugs; explaining why other authors restricted their systematic reviews of beta‐blocker therapy to trials where confounding supplementary drug classes were administered to less than half of participants ([Wright 1999](#CD002003-bbs2-0104){ref-type="ref-list"}; [Wright 2000](#CD002003-bbs2-0105){ref-type="ref-list"}; [Wright 2009](#CD002003-bbs2-0106){ref-type="ref-list"}). Although we were less restrictive than Wright and colleagues ([Wright 1999](#CD002003-bbs2-0104){ref-type="ref-list"}; [Wright 2000](#CD002003-bbs2-0105){ref-type="ref-list"}), we included only trials in which all the participants in one group received a beta‐blocker at baseline, whether or not other antihypertensive drug classes were later added to achieve blood pressure targets. This requirement was in contrast to other systematic reviews ([Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}; [Dahlöf 2007](#CD002003-bbs2-0053){ref-type="ref-list"}; [Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}; [Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}). The dropout rates were high in two of the studies of diuretics, potentially introducing attrition bias ([MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}).

It may be that only people with complicated hypertension or advanced disease are included in most studies, thereby ignoring the possible differing benefits of different antihypertensive medications on different organs and on different stages of disease development ([Zanchetti 2005](#CD002003-bbs2-0107){ref-type="ref-list"}). A further problem is that in the two groups of the studies we analysed, and especially in the case of the comparison with diuretics, there were discrepancies between the achieved blood pressure levels ([Table 10](#CD002003-tbl-0010){ref-type="table"}), and even small blood pressure differences may be linked to significant differences in outcomes ([Collins 1990](#CD002003-bbs2-0052){ref-type="ref-list"}; [Staessen 2003](#CD002003-bbs2-0095){ref-type="ref-list"}). However, there were no consistent differences in the blood pressure reduction between beta‐blockers and the other agents used to explain the outcome differences we found ([Table 10](#CD002003-tbl-0010){ref-type="table"}). Yet another limitation is that (due to the scarcity of relevant trials) we combined the potentially different classes of RAS inhibitors (i.e. ACE inhibitors (captopril and lisinopril) and ARB (losartan). However, we believe that the similarities between these agents as antihypertensive drugs outweigh any potential differences.

Potential biases in the review process {#CD002003-sec2-0014}
--------------------------------------

We minimised potential biases in the review process by adhering to the Cochrane guidelines ([Higgins 2011](#CD002003-bbs2-0061){ref-type="ref-list"}). We conducted a comprehensive search for eligible studies, without limiting the search to a specific language. Two review authors independently assessed study eligibility, extracted data, and assessed the risk of bias in each included study.

Agreements and disagreements with other studies or reviews {#CD002003-sec2-0015}
----------------------------------------------------------

We showed that beta‐blockers are inferior to various CCBs for all‐cause mortality, stroke, and total cardiovascular events, and to RAS inhibition for stroke. By comparing beta‐blockers with all other therapies, Lindholm and colleagues were only able to show an inferiority of beta‐blockade on stroke reduction ([Carlberg 2004](#CD002003-bbs2-0050){ref-type="ref-list"}; [Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}). In a similar meta‐analysis, Khan and McAlister found beta‐blockers to be inferior to all other therapies in effects on a composite outcome of major cardiovascular events (stroke, myocardial infarction, and death) and stroke for older people with hypertension but found no difference in effects for younger people ([Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"}). The claim by [Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"} that the defects of beta‐blockade are limited to older people relies heavily on the Medical Research Council trial in older people with hypertension in which the beta‐blocker was atenolol and where the dropout rate was 25% ([MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}). In addition, [Khan 2006](#CD002003-bbs2-0068){ref-type="ref-list"} classified trials which enrolled participants as young as 40 ([ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}), 45 ([ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}), and 50 ([INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}) years as trials of older people with hypertension. At present, there are insufficient data to make a valid comparison of beta‐blocker effects on younger versus older people, although this is an important hypothesis.

We used the I^2^ statistic to evaluate the consistency in study results ([Higgins 2003](#CD002003-bbs2-0060){ref-type="ref-list"}; [Higgins 2011](#CD002003-bbs2-0061){ref-type="ref-list"}). In our meta‐analyses, heterogeneity was very low for the outcomes of beta‐blockers versus placebo or no treatment. We found a modest 20% relative reduction in stroke by beta‐blockers compared to placebo with six studies, which is similar to the relative reduction reported by Lindholm and colleagues using seven studies ([Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}). With their wider inclusion criteria, Lindholm and colleagues included three studies not considered by us ([Dutch TIA 1993](#CD002003-bbs2-0028){ref-type="ref-list"}; [STOP 1991](#CD002003-bbs2-0039){ref-type="ref-list"}; [TEST 1995](#CD002003-bbs2-0041){ref-type="ref-list"}), which resulted in significant heterogeneity of effect in their findings. By contrast, there was excellent homogeneity of effect with the four studies included in our comparison of beta‐blockers to placebo as shown by an I^2^ value of 0% ([Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}; [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}). Thus, we were able to give additional validation to one of the crucial findings of Lindholm and colleagues ([Lindhom 2005](#CD002003-bbs2-0071){ref-type="ref-list"}), namely that stroke reduction by beta‐blockade is suboptimal.

Two other reviews also differed from ours in their inclusion or exclusion of various studies ([Dahlöf 2007](#CD002003-bbs2-0053){ref-type="ref-list"}; [Wright 2009](#CD002003-bbs2-0106){ref-type="ref-list"}). Both considered the [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"} as a placebo‐controlled trial and excluded [IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}. In addition, [Wright 2009](#CD002003-bbs2-0106){ref-type="ref-list"} excluded [Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"} because of high use of diuretics in the beta‐blocker group while [Dahlöf 2007](#CD002003-bbs2-0053){ref-type="ref-list"} included [STOP 1991](#CD002003-bbs2-0039){ref-type="ref-list"} because more than 85% of participants on active treatment received beta‐blocker as first‐line or second‐line therapy. Both reviews considered the \"less tight control group\" in [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"} as \"placebo\" because the target for blood pressure reduction in this group was not as low as in the beta‐blocker group. However, participants in this control group took antihypertensive treatment for 57% of their total person‐years in the [UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"} trial.

We combined trials of low‐dose and high‐dose thiazide diuretics because of the paucity of trials comparing beta‐blockers to diuretics ([Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}; [HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}; [MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}; [MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}; [VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}). This may be the reason for the lack of a statistical difference between beta‐blockers and diuretics in our review, since Wright and Musini have shown that first‐line low‐dose thiazides reduce stroke, CHD, and mortality outcomes while first‐line high‐dose thiazides have no significant effects on mortality and CHD ([Wright 2009](#CD002003-bbs2-0106){ref-type="ref-list"}).

We conducted sensitivity analyses and found our results to be consistent with those of the related reviews, despite differences in inclusion and exclusion criteria ([Effects of interventions](#CD002003-sec2-0010){ref-type="sec"}). Overall, despite a variation in the studies included in other beta‐blocker reviews arising from different interpretations of inclusion criteria, all the reviews arrived at similar conclusions that the available evidence does not support the use of beta‐blockers as first‐line drugs in the treatment of hypertension.

Authors\' conclusions {#CD002003-sec1-0007}
=====================

Implications for practiceFirst‐line beta‐blockers in people with hypertension lead to modest reductions in stroke and have no significant effects on total mortality and coronary heart disease. In addition, beta‐blockers are inferior to calcium‐channel blockers and renin‐angiotensin system inhibitors for various important outcomes. Most of this evidence is considered to be of low quality according to the GRADE system, implying that further research is likely to change our confidence in the estimate of these effects. However, the evidence comes mainly from trials that used atenolol. Our findings extend the results of previous meta‐analyses suggesting that beta‐blockers are inferior first‐line choices when compared to diuretics, renin‐angiotensin system inhibitors, and calcium‐channel blockers.

Implications for researchMore randomised controlled trials studying the use of beta‐blockers for elevated blood pressure are required. Such hypertension trials must measure clearly defined morbidity and mortality endpoints, including coronary heart disease, heart failure, and stroke. These trials should be used to define differences between beta‐blockers and other classes of antihypertensive drugs and between the different subclasses of beta‐blockers. In addition, the possible differential effect of beta‐blockers on younger and older people needs to be assessed in future hypertension trials.

What\'s new {#CD002003-sec1-0013}
===========

**DateEventDescription**12 January 2017New search has been performedUp to date search. No new studies met the inclusion criteria.12 January 2017New citation required but conclusions have not changedConclusions have been reworded and there is a change in authorship and author affiliations.

History {#CD002003-sec1-0014}
=======

Protocol first published: Issue 3, 1998  Review first published: Issue 1, 2007

**DateEventDescription**16 November 2012AmendedNew search from December 2011 to November 2012.27 August 2012Amendedupdated author affiliations9 July 2012New search has been performedNew search from June 2006 to December 2011. No new studies met the inclusion criteria. The Risk of Bias table has been updated for all included studies and 4 Summary of findings tables have been added to the updated review. In the 2007 version there were unintended errors in the data entered for withdrawals due to side effects for the two UK Medical Research Council trials ([MRC 1985,](#CD002003-bbs2-0010){ref-type="ref-list"}[MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}), which led to the erroneous conclusion that patients on beta‐blockers were more likely to discontinue treatment due to side effects than those on diuretics. The corrected data, in this update, show no significant differences in withdrawals due to side effects between beta‐blockers and diuretics. The overall message in the conclusions has not changed.9 July 2012New citation required but conclusions have not changedNew citation due to update13 August 2008AmendedConverted to new review format.

We thank the staff of the Cochrane Hypertension Group for assistance during the update of this systematic review. We acknowledge the significant contributions of Professor Anthony Mbewu and Dr Roy Maroney to the protocol and previous versions of the review. Professor Mbewu and Dr Maroney did not contribute to and have neither read nor approved the current review.
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 3 (beta adj2 (adrenergic? or antagonist? or block\$ or receptor?)).tw. (104425)  4 or/1‐3 (294052)  5 exp hypertension/ (510805)  6 hypertens\$.tw. (448067)  7 exp blood pressure/ (413025)  8 blood pressure o bloodpressure.mp. (0)  9 or/5‐8 (911302)  10 randomized controlled trial/ (358482)  11 crossover procedure/ (41032)  12 double‐blind procedure/ (119385)  13 (randomi?ed or randomly).tw. (749012)  14 (crossover\$ or cross‐over\$).tw. (73500)  15 placebo\$.ab. (204404)  16 (doubl\$ adj blind\$).tw. (152473)  17 assign\$.ab. (245912)  18 allocat\$.ab. (86645)  19 or/10‐18 (1145599)  20 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.) (5518138)  21 19 not 20 (995733)  22 4 and 9 and 21 (11880)  23 22 and (2013\$ or 2014\$ or 2015\$).em. (1164)  24 remove duplicates from 23 (1150)

**Cochrane Central Register of Controlled Trials on Wiley \<Issue 1, 2015\> via Cochrane Register of Studies Online**   Search Date: 19 January 2015  ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  \#1:(adrenergic beta‐antagonist\*) ‐ 3953  \#2: (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol) ‐ 14056  \#3: beta near2 (adrenergic\* or antagonist\* or block\* or receptor\*) ‐ 11011  \#4: \#1 OR \#2 OR \#3 ‐ 18403  \#5: antihypertens\* or hypertens\* ‐ 35486  \#6: (\"blood pressure\" or bloodpressure) ‐ 46400  \#7: \#5 OR \#6 ‐ 63228  \#8: \#4 AND \#7 ‐ 9332  \#9: 01/10/2013 TO 19/01/2015:CD ‐ 123974  \#10: \#8 AND \#9 ‐ 793    \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Hypertension Group Specialised Register**   Search Date: 19 January 2015  ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐    1 (adrenergic beta‐antagonist\*)  2 (beta blocker\*)  3 (beta adrenergic block\*)  4 (adrenergic beta receptor block\*)  5 (beta adrenergic receptor block\*)  6 \#1 OR \#2 OR \#3 OR \#4 OR \#5  7 (hypertens\*)  8 \#6 AND \#7  9 \#8 AND (RCT OR Review OR Meta‐Analysis) (1782)    \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**ClinicalTrials.gov (via Cochrane Register of Studies)**   Search Date: 19 January 2015  ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  Search terms: randomized  Study type: Interventional  Conditions: hypertension  Interventions: \"adrenergic beta‐antagonist\" OR \"adrenergic beta‐antagonists\" OR \"beta blocker\" OR \"beta blockers\"  Outcome Measures: blood pressure  First received: 1/10/2013 to 19/1/2015 (9)    \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Ovid MEDLINE(R) 1946 to Present with Daily Update**   Search Date: 14 June 2016  ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  1 exp adrenergic beta‐antagonists/ (79179)    2 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol).mp. (75673)    3 (beta adj2 (adrenergic? or antagonist? or block\$ or receptor?)).tw. (90482)    4 or/1‐3 (145660)    5 hypertension/ (210798)    6 hypertens\$.tw. (330792)    7 exp blood pressure/ (264762)    8 (blood pressure or blood pressure).mp. (373969)    9 or/5‐8 (633729)    10 randomized controlled trial.pt. (420851)    11 controlled clinical trial.pt. (91010)    12 randomi?ed.ab. (379711)    13 placebo.ab. (159968)    14 drug therapy.fs. (1873762)    15 randomly.ab. (223574)    16 trial.ab. (328035)    17 groups.ab. (1409370)    18 or/10‐17 (3572728)    19 animals/ not (humans/ and animals/) (4231241)    20 18 not 19 (3046252)    21 4 and 9 and 20 (20003)    22 21 and (2015\$ or 2016\$).ed. (528)    23 remove duplicates from 22 (498)    \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Cochrane Central Register of Controlled Trials on Wiley \<2016, Issue 6\> via Cochrane Register of Studies Online**   Search Date: 14 June 2016  ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  \#1MESH DESCRIPTOR Adrenergic beta‐Antagonists EXPLODE ALL TREES9429  \#2adrenergic beta‐antagonist\*4072  \#3(acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol)14950  \#4beta near2 (adrenergic\* or antagonist\* or block\* or receptor\*)12693  \#5\#1 OR \#2 OR \#3 OR \#420606  \#6antihypertens\* or hypertens\*40964  \#7blood pressure or bloodpressure52553  \#8\#6 OR \#772648  \#9\#5 AND \#810268  \#1001/01/2015 TO 14/06/2016:CD AND 01/01/2015 TO 14/06/2016:CD107219  \#11\#9 AND \#10558    \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Embase \<1974 to 2016 June 13\>**   Search Date: 14 June 2016  ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  1 exp beta adrenergic receptor blocking agent/ (257952)    2 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol).mp. (186549)    3 (beta adj2 (adrenergic? or antagonist? or block\$ or receptor?)).tw. (112699)    4 or/1‐3 (312536)    5 exp hypertension/ (577705)    6 hypertens\$.tw. (508421)    7 exp blood pressure/ (464921)    8 blood pressure o bloodpressure.mp. (0)    9 or/5‐8 (1027859)    10 randomized controlled trial/ (408424)    11 crossover procedure/ (47399)    12 double‐blind procedure/ (131405)    13 (randomi?ed or randomly).tw. (880104)    14 (crossover\$ or cross‐over\$).tw. (82444)    15 placebo\$.ab. (231893)    16 (doubl\$ adj blind\$).tw. (169466)    17 assign\$.ab. (283020)    18 allocat\$.ab. (102246)    19 or/10‐18 (1321527)    20 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.) (5874427)    21 19 not 20 (1153534)    22 4 and 9 and 21 (12623)    23 22 and (2015\$ or 2016\$).em. (818)    24 remove duplicates from 23 (795)    \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**Cochrane Hypertension Specialised Register**   Search Date: Search Date: 14 June 2016  ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  \#1 (adrenergic beta‐antagonist\*) (1506)  \#2 (beta blocker\*) (2211)  \#3 (beta adrenergic block\*) (247)  \#4 (adrenergic beta receptor block\*) (13)  \#5 (beta adrenergic receptor block\*) (1141)  \#6 \#1 OR \#2 OR \#3 OR \#4 OR \#5 (3838)  \#7 RCT:DE (22671)  \#8 (Review or Meta‐Analysis):MISC2 (1147)  \#9 \#6 AND (\#7 OR \#8) (2176)  \#10 (\#9) AND (1/1/2015 TO 14/6/2016:CRSMODIFIED) (398)    \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**ClinicalTrials.gov**   Search Date: 14 June 2016  ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  Search terms: randomized  Study type: Interventional  Conditions: hypertension   Interventions: \"adrenergic beta‐antagonist\" OR \"adrenergic beta‐antagonists\" OR \"beta blocker\" OR \"beta blockers\"  Outcome Measures: blood pressure (95)    \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

###### Beta‐blocker versus placebo or no treatment

  Outcome or subgroup title                                                    No. of studies   No. of participants   Statistical method                 Effect size
  ---------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Mortality](#CD002003-fig-00101){ref-type="fig"}                           4                23613                 Risk Ratio (M‐H, Fixed, 95% CI)    0.99 \[0.88, 1.11\]
  [2 Total stroke](#CD002003-fig-00102){ref-type="fig"}                        4                23613                 Risk Ratio (M‐H, Fixed, 95% CI)    0.80 \[0.66, 0.96\]
  [3 Total coronary heart disease](#CD002003-fig-00103){ref-type="fig"}        4                23613                 Risk Ratio (M‐H, Fixed, 95% CI)    0.93 \[0.81, 1.07\]
  [4 Cardiovascular death](#CD002003-fig-00104){ref-type="fig"}                4                23613                 Risk Ratio (M‐H, Fixed, 95% CI)    0.93 \[0.80, 1.09\]
  [5 Total cardiovascular disease](#CD002003-fig-00105){ref-type="fig"}        4                23613                 Risk Ratio (M‐H, Fixed, 95% CI)    0.88 \[0.79, 0.97\]
  [6 Withdrawal due to adverse effects](#CD002003-fig-00106){ref-type="fig"}   3                                      Risk Ratio (M‐H, Random, 95% CI)   Totals not selected
  6.1 Oxprenolol                                                               1                                      Risk Ratio (M‐H, Random, 95% CI)   0.0 \[0.0, 0.0\]
  6.2 Propranolol                                                              1                                      Risk Ratio (M‐H, Random, 95% CI)   0.0 \[0.0, 0.0\]
  6.3 Atenolol                                                                 1                                      Risk Ratio (M‐H, Random, 95% CI)   0.0 \[0.0, 0.0\]

![Analysis\
Comparison 1 Beta‐blocker versus placebo or no treatment, Outcome 1 Mortality.](nCD002003-CMP-001-01){#CD002003-fig-00101}

![Analysis\
Comparison 1 Beta‐blocker versus placebo or no treatment, Outcome 2 Total stroke.](nCD002003-CMP-001-02){#CD002003-fig-00102}

![Analysis\
Comparison 1 Beta‐blocker versus placebo or no treatment, Outcome 3 Total coronary heart disease.](nCD002003-CMP-001-03){#CD002003-fig-00103}

![Analysis\
Comparison 1 Beta‐blocker versus placebo or no treatment, Outcome 4 Cardiovascular death.](nCD002003-CMP-001-04){#CD002003-fig-00104}

![Analysis\
Comparison 1 Beta‐blocker versus placebo or no treatment, Outcome 5 Total cardiovascular disease.](nCD002003-CMP-001-05){#CD002003-fig-00105}

![Analysis\
Comparison 1 Beta‐blocker versus placebo or no treatment, Outcome 6 Withdrawal due to adverse effects.](nCD002003-CMP-001-06){#CD002003-fig-00106}

###### Beta‐blocker versus diuretic

  Outcome or subgroup title                                                    No. of studies   No. of participants   Statistical method                 Effect size
  ---------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Mortality](#CD002003-fig-00201){ref-type="fig"}                           5                18241                 Risk Ratio (M‐H, Fixed, 95% CI)    1.04 \[0.91, 1.19\]
  [2 Total stroke](#CD002003-fig-00202){ref-type="fig"}                        4                18135                 Risk Ratio (M‐H, Random, 95% CI)   1.17 \[0.65, 2.09\]
  2.1 Cardio‐selective beta‐blocker                                            3                9435                  Risk Ratio (M‐H, Random, 95% CI)   0.92 \[0.55, 1.54\]
  2.2 Non‐selective beta‐blocker                                               1                8700                  Risk Ratio (M‐H, Random, 95% CI)   2.28 \[1.31, 3.95\]
  [3 Total coronary heart disease](#CD002003-fig-00203){ref-type="fig"}        4                18135                 Risk Ratio (M‐H, Random, 95% CI)   1.12 \[0.82, 1.54\]
  3.1 Aged \< 65 years                                                         3                15952                 Risk Ratio (M‐H, Random, 95% CI)   0.97 \[0.81, 1.17\]
  3.2 Aged \> 65 years                                                         1                2183                  Risk Ratio (M‐H, Random, 95% CI)   1.63 \[1.15, 2.32\]
  [4 Cardiovascular death](#CD002003-fig-00204){ref-type="fig"}                3                17452                 Risk Ratio (M‐H, Fixed, 95% CI)    1.09 \[0.90, 1.32\]
  [5 Total cardiovascular disease](#CD002003-fig-00205){ref-type="fig"}        4                18135                 Risk Ratio (M‐H, Fixed, 95% CI)    1.13 \[0.99, 1.28\]
  [6 Withdrawal due to adverse effects](#CD002003-fig-00206){ref-type="fig"}   3                11566                 Risk Ratio (M‐H, Random, 95% CI)   1.69 \[0.95, 3.00\]

![Analysis\
Comparison 2 Beta‐blocker versus diuretic, Outcome 1 Mortality.](nCD002003-CMP-002-01){#CD002003-fig-00201}

![Analysis\
Comparison 2 Beta‐blocker versus diuretic, Outcome 2 Total stroke.](nCD002003-CMP-002-02){#CD002003-fig-00202}

![Analysis\
Comparison 2 Beta‐blocker versus diuretic, Outcome 3 Total coronary heart disease.](nCD002003-CMP-002-03){#CD002003-fig-00203}

![Analysis\
Comparison 2 Beta‐blocker versus diuretic, Outcome 4 Cardiovascular death.](nCD002003-CMP-002-04){#CD002003-fig-00204}

![Analysis\
Comparison 2 Beta‐blocker versus diuretic, Outcome 5 Total cardiovascular disease.](nCD002003-CMP-002-05){#CD002003-fig-00205}

![Analysis\
Comparison 2 Beta‐blocker versus diuretic, Outcome 6 Withdrawal due to adverse effects.](nCD002003-CMP-002-06){#CD002003-fig-00206}

###### Beta‐blocker versus calcium‐channel blocker (CCB)

  Outcome or subgroup title                                                    No. of studies   No. of participants   Statistical method                 Effect size
  ---------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Mortality](#CD002003-fig-00301){ref-type="fig"}                           4                44825                 Risk Ratio (M‐H, Fixed, 95% CI)    1.07 \[1.00, 1.14\]
  [2 Total stroke](#CD002003-fig-00302){ref-type="fig"}                        3                44167                 Risk Ratio (M‐H, Fixed, 95% CI)    1.24 \[1.11, 1.40\]
  [3 Total coronary heart disease](#CD002003-fig-00303){ref-type="fig"}        3                44167                 Risk Ratio (M‐H, Fixed, 95% CI)    1.05 \[0.96, 1.15\]
  [4 Cardiovascular death](#CD002003-fig-00304){ref-type="fig"}                4                44825                 Risk Ratio (M‐H, Random, 95% CI)   1.15 \[0.92, 1.46\]
  [5 Total cardiovascular disease](#CD002003-fig-00305){ref-type="fig"}        2                19915                 Risk Ratio (M‐H, Fixed, 95% CI)    1.18 \[1.08, 1.29\]
  [6 Withdrawal due to adverse effects](#CD002003-fig-00306){ref-type="fig"}   2                21591                 Risk Ratio (M‐H, Random, 95% CI)   1.20 \[0.71, 2.04\]

![Analysis\
Comparison 3 Beta‐blocker versus calcium‐channel blocker (CCB), Outcome 1 Mortality.](nCD002003-CMP-003-01){#CD002003-fig-00301}

![Analysis\
Comparison 3 Beta‐blocker versus calcium‐channel blocker (CCB), Outcome 2 Total stroke.](nCD002003-CMP-003-02){#CD002003-fig-00302}

![Analysis\
Comparison 3 Beta‐blocker versus calcium‐channel blocker (CCB), Outcome 3 Total coronary heart disease.](nCD002003-CMP-003-03){#CD002003-fig-00303}

![Analysis\
Comparison 3 Beta‐blocker versus calcium‐channel blocker (CCB), Outcome 4 Cardiovascular death.](nCD002003-CMP-003-04){#CD002003-fig-00304}

![Analysis\
Comparison 3 Beta‐blocker versus calcium‐channel blocker (CCB), Outcome 5 Total cardiovascular disease.](nCD002003-CMP-003-05){#CD002003-fig-00305}

![Analysis\
Comparison 3 Beta‐blocker versus calcium‐channel blocker (CCB), Outcome 6 Withdrawal due to adverse effects.](nCD002003-CMP-003-06){#CD002003-fig-00306}

###### Beta‐blocker versus renin‐angiotensin system (RAS) inhibitor

  Outcome or subgroup title                                                    No. of studies   No. of participants   Statistical method                 Effect size
  ---------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Mortality](#CD002003-fig-00401){ref-type="fig"}                           3                10828                 Risk Ratio (M‐H, Fixed, 95% CI)    1.10 \[0.98, 1.24\]
  [2 Total stroke](#CD002003-fig-00402){ref-type="fig"}                        2                9951                  Risk Ratio (M‐H, Fixed, 95% CI)    1.30 \[1.11, 1.53\]
  [3 Total coronary heart disease](#CD002003-fig-00403){ref-type="fig"}        2                9951                  Risk Ratio (M‐H, Fixed, 95% CI)    0.90 \[0.76, 1.06\]
  [4 Cardiovascular death](#CD002003-fig-00404){ref-type="fig"}                3                10828                 Risk Ratio (M‐H, Fixed, 95% CI)    1.09 \[0.92, 1.29\]
  [5 Total cardiovascular disease](#CD002003-fig-00405){ref-type="fig"}        3                10828                 Risk Ratio (M‐H, Random, 95% CI)   1.00 \[0.72, 1.38\]
  5.1 Angiotensin‐converting enzyme inhibitors                                 2                1635                  Risk Ratio (M‐H, Random, 95% CI)   0.81 \[0.63, 1.04\]
  5.2 Angiotensin receptor blockers                                            1                9193                  Risk Ratio (M‐H, Random, 95% CI)   1.16 \[1.04, 1.30\]
  [6 Withdrawal due to adverse effects](#CD002003-fig-00406){ref-type="fig"}   2                9951                  Risk Ratio (M‐H, Fixed, 95% CI)    1.41 \[1.29, 1.54\]

![Analysis\
Comparison 4 Beta‐blocker versus renin‐angiotensin system (RAS) inhibitor, Outcome 1 Mortality.](nCD002003-CMP-004-01){#CD002003-fig-00401}

![Analysis\
Comparison 4 Beta‐blocker versus renin‐angiotensin system (RAS) inhibitor, Outcome 2 Total stroke.](nCD002003-CMP-004-02){#CD002003-fig-00402}

![Analysis\
Comparison 4 Beta‐blocker versus renin‐angiotensin system (RAS) inhibitor, Outcome 3 Total coronary heart disease.](nCD002003-CMP-004-03){#CD002003-fig-00403}

![Analysis\
Comparison 4 Beta‐blocker versus renin‐angiotensin system (RAS) inhibitor, Outcome 4 Cardiovascular death.](nCD002003-CMP-004-04){#CD002003-fig-00404}

![Analysis\
Comparison 4 Beta‐blocker versus renin‐angiotensin system (RAS) inhibitor, Outcome 5 Total cardiovascular disease.](nCD002003-CMP-004-05){#CD002003-fig-00405}

![Analysis\
Comparison 4 Beta‐blocker versus renin‐angiotensin system (RAS) inhibitor, Outcome 6 Withdrawal due to adverse effects.](nCD002003-CMP-004-06){#CD002003-fig-00406}

Characteristics of included studies \[ordered by study ID\] {#CD002003-sec2-0020}
===========================================================

[AASK 2002](#CD002003-bbs2-0001){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: described as randomised controlled trial, but method of allocating participants to treatment was not described.\
Blinding: participants, providers, and outcome assessors blinded\
Loss to follow‐up: 0%\
Mean duration of follow‐up: 4.1 years\
Analyses: by intention‐to‐treatParticipantsGeographic location: USA\
Study setting: hospital\
Number of participants: 1094 (61.2% men)\
Age range: 18 to 70 years (mean: 54 years)\
Entry criteria: DBP ≥ 95 mmHg (mean BP 150/96 mmHg) and glomerular filtration rate 20 mL/minute/1.73 m^2^ to 65 mL/minute/1.73 m^2^ and no other identified causes of renal insufficiency\
Race: all African Americans\
Exclusion criteria: DBP \< 95 mmHg, known history of diabetes mellitus, urinary protein to creatinine ratio \> 2.5, accelerated or malignant hypertension within 6 months, secondary hypertension, non‐BP‐related causes of kidney disease, serious systemic disease, clinical CHF, or specific (contra)indication for a study drug or procedureInterventions**Beta‐blocker group:**\
Metoprolol 50 mg/day to 200 mg/day\
**ACE inhibitor group:**\
Ramipril 2.5 mg/day to 10 mg/day\
**Calcium‐channel blocker group:**\
Amlodipine 5 mg/day to 10 mg/day\
If the BP goal could not be achieved by the randomly allocated drug, additional open‐labelled antihypertensive drugs were added sequentially.OutcomesCardiovascular events\
Cardiovascular mortality\
All‐cause mortalityNotesA formal stopping rule was constructed based on the primary renal function analysis with separate O\'Brien‐Fleming boundaries for the chronic and total mean slopes for each of the 3 primary treatment group comparisons. The stopping rule stipulated that a treatment group should be discontinued at 1 of the study\'s annual interim analyses if the stopping boundaries indicating faster progression were crossed in the same direction for both the chronic and total mean slopes.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskDescribed as \"randomly allocated\"Blinding of participants and personnel (performance bias)   All outcomesLow riskParticipants and personnel blindedBlinding of outcome assessment (detection bias)   All outcomesLow riskBlind outcome assessmentIncomplete outcome data (attrition bias)   All outcomesLow riskLoss to follow‐up: 0%\
Participants withdrawing from the study were accounted for in an intention‐to‐treat analysis.Selective reporting (reporting bias)Low riskReported all outcomes as stated in protocolOther biasUnclear riskAmlodipine group terminated early at recommendation of Data and Safety Monitoring Board, according to predetermined stopping rules.\
Other antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[ASCOT 2005](#CD002003-bbs2-0002){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: computer‐generated, using separate lists for each co‐ordinating centre. Participating physicians called the co‐ordinating centre to obtain the treatment allocation for each participant. Open treatment and blinded endpoint evaluation (PROBE) design.\
Loss to follow‐up: 0.3% withdrew consent and 0.3% lost to follow‐up\
Median duration of follow‐up: 5.5 years\
Analyses: by intension‐to‐treatParticipantsGeographic location: UK, Ireland, Denmark, Finland, Iceland, Norway, and Sweden\
Study setting: hospital and primary care\
Number of participants: 19,257 (76.6% men)\
Age range: 40 to 79 years (mean: 63 years)\
Entry criteria: sitting SBP ≥ 160 with or without DBP ≨ 100 mmHg (for people with untreated hypertension) OR SBP ≥ 140 with or without DBP ≥ 90 mmHg (for people taking antihypertensive treatment), and 3 CHD risk factors.\
Race: 95% white\
Exclusion criteria: previous MI, current angina, cerebrovascular event in previous 3 months, fasting triglycerides \> 4.5 mmol/L, heart failure, uncontrolled arrhythmias, or any clinically important haematological or biochemical abnormality on routine screening\
Comorbid conditions: current smoking (33%), LVH (22%), type 2 diabetes (27%); peripheral arterial disease (6%), previous stroke or TIA (11%), microalbuminuria, obesity, hyperlipidaemiaInterventions**Beta‐blocker group:**\
Step 1: atenolol 50 mg\
Step 2: atenolol 100 mg\
Step 3: atenolol 100 mg + bendroflumethiazide 1.25 mg + potassium\
Step 4: atenolol 100 mg + bendroflumethiazide 2.5 mg + potassium\
Step 5: atenolol 100 mg + bendroflumethiazide 2.5 mg + potassium + doxazosin gastrointestinal transport system 4 mg\
Step 6: atenolol 100 mg + bendroflumethiazide 2.5 mg + potassium + doxazosin gastrointestinal transport system 8 mg\
Further treatment to achieve BP goal added, as required\
**Calcium‐channel blocker group:**\
Step 1: amlodipine 5 mg\
Step 2: amlodipine 10 mg\
Step 3: amlodipine 10 mg + perindopril 4 mg\
Step 4: amlodipine 10 mg + perindopril 8 mg (2 × 4 mg)\
Step 5: amlodipine 10 mg + perindopril 8 mg (2 × 4 mg) + doxazosin gastrointestinal transport system 4 mg\
Step 6: amlodipine 10 mg + perindopril 8 mg (2 × 4 mg) + doxazosin gastrointestinal transport system 8 mg\
Further treatment to BP goal added, as required.\
On average, of total time, 79% were taking atenolol and 83% were taking amlodipine. At the end of the study, 9% were taking atenolol monotherapy and 15% taking amlodipine monotherapy.OutcomesPrimary outcome: combined endpoint of non‐fatal MI (including silent MI) and fatal CHD\
Secondary outcomes: all‐cause mortality, total stroke, primary endpoint minus silent MI, all coronary events, total cardiovascular events and procedures, cardiovascular mortality, and non‐fatal and fatal heart failure\
Tertiary outcomes: silent MI, unstable angina, chronic stable angina, peripheral arterial disease, life‐threatening arrhythmias, development of diabetes, development of renal impairment, and the effects on the primary endpoint and on total cardiovascular events and procedures among prespecified subgroupsNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generatedAllocation concealment (selection bias)Low riskCentral randomisationBlinding of participants and personnel (performance bias)   All outcomesHigh riskOpen treatmentBlinding of outcome assessment (detection bias)   All outcomesLow riskBlinded outcome assessmentIncomplete outcome data (attrition bias)   All outcomesUnclear risk0.3% withdrew consent and 0.3% were lost to follow‐up. Not indicated whether reasons for missing outcome data were similar across treatment groups.Selective reporting (reporting bias)Low riskReported all outcomes as stated in protocolOther biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[Berglund 1981](#CD002003-bbs2-0003){ref-type="ref-list"}MethodsSingle‐centre study\
Randomisation: described as randomised controlled trial, but method of allocating participants to treatment was not described.\
Blinding: not known if participants, providers, or assessors blinded\
Loss to follow‐up: 7%\
Mean duration of follow‐up: 10 years\
Analyses: by intention‐to‐treatParticipantsGeographic region: Sweden\
Study setting: hospital\
Number of participants: 106 (all men)\
Age range: 47 to 54 years (mean: 50.8 years)\
Race: not reported\
BP at entry: \> 170/105 mmHg\
Comorbid conditions: not mentionedInterventions**Beta‐blocker group:**\
Step 1: propranolol 80 mg twice daily\
Step 2: propranolol 160 mg twice daily\
Step 3: propranolol 160 mg twice daily + hydralazine 25 mg to 50 mg twice daily\
Step 4: propranolol 160 mg twice daily + hydralazine 25 mg to 50 mg twice daily + other antihypertensive drugs\
**Diuretic group:**\
Step 1: bendroflumethiazide 2.5 mg once daily\
Step 2: bendroflumethiazide 5 mg once daily\
Step 3: bendroflumethiazide 5 mg once daily + hydralazine 25 mg to 50 mg twice daily\
Step 4: bendroflumethiazide 5 mg once daily + hydralazine 25 mg to 50 mg twice daily + other antihypertensive drugs\
At the end of trial, 74% were taking propranolol and 70% were taking bendroflumethiazide; with 42% taking propranolol and 40% taking bendroflumethiazide monotherapy.OutcomesTotal mortalityNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskDescribed as randomised controlled trial, but method of allocating participants to treatment was not described.Blinding of participants and personnel (performance bias)   All outcomesHigh riskCompletely unblindedBlinding of outcome assessment (detection bias)   All outcomesLow riskThere was no blinding of outcome assessment, but the outcome assessed (i.e. death) is unlikely to be influenced by lack of blindingIncomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up: 7%. Not indicated whether reasons for missing outcome data were similar across treatment groups.Selective reporting (reporting bias)Unclear riskNo access to the protocol.Other biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[Coope 1986](#CD002003-bbs2-0004){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: participants were randomised on a 50:50 basis without stratification using random number tables. Opaque envelopes were supplied in sequence from the trial administrative centre that gave instructions for allocation to treatment or control group.\
Loss to follow‐up: not stated\
Mean duration of follow‐up: 4.4 yearsParticipantsGeographic region: England and Wales\
Study setting: primary care\
Number of participants: 884 (31% men)\
Age range: 60 to 79 years (mean: 65 years)\
Race: not stated\
Exclusion criteria: atrial fibrillation, A‐V heart block, ventricular failure, bronchial asthma, diabetes mellitus (needing pharmacological treatment) or any serious concomitant disease, and untreated hypertension with levels persistently \> 280 mmHg for SBP or 120 mmHg for DBP or people already being treated for hypertension (within 3 months)\
Mean BP at entry: 196.4/98.8 mmHg\
BP entry criteria: not stated\
Comorbid conditions: smoking 215 (24%)Interventions**Beta‐blocker group:**\
Step 1: atenolol 100 mg/day\
Step 2: bendrofluazide 5 mg/day\
Step 3: methyldopa 500 mg/day\
Step 4: any other recognised therapy such as nifedipine retard 20 mg twice daily\
**Control group:**\
No treatment\
Proportion on assigned treatment at end of study: beta‐blocker group: 70%OutcomesTotal mortality\
CHD mortality: fatal MI, sudden death\
CHD morbidity: non‐fatal MI\
Cerebrovascular mortality: fatal stroke\
Cerebrovascular morbidity: non‐fatal stroke\
Cardiovascular mortality: fatal stroke, MI, sudden death, ventricular failure, ruptured aneurysm, hypertensive nephropathy\
Cardiovascular morbidity: non‐fatal stroke, MI, non‐fatal ventricular failureNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskUsed random number tableAllocation concealment (selection bias)Low riskUsed opaque sequentially numbered envelopes supplied by the trial administrative centreBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot statedBlinding of outcome assessment (detection bias)   All outcomesLow riskBlind outcome assessmentIncomplete outcome data (attrition bias)   All outcomesUnclear riskNot indicated whether reasons for missing outcome data were similar across treatment groupsSelective reporting (reporting bias)Unclear riskNo access to protocolOther biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[ELSA 2002](#CD002003-bbs2-0005){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: computer‐generated, using separate lists for each centre with a block size of 4. Participants and study personnel, excluding the Safety Committee, were blinded to treatment assignment for study duration\
Loss to follow‐up: 3.9%\
Mean duration of follow‐up: 3.75 years\
Analyses: by intention‐to‐treatParticipantsGeographic location: France, Germany, Greece, Italy, Spain, Sweden, UK\
Study setting: 410 clinical units\
Number of participants: 2334 (54.8% men)\
Age range: 45 to 75 years (mean: 56 years)\
Entry criteria: sitting SBP 150 mmHg to 210 mmHg and DBP 95 mmHg to 115 mmHg, fasting serum total cholesterol concentration ≤ 320 mg/dL, fasting serum triglyceride concentration ≤ 300 mg/dL, and serum creatinine concentration ≤ 1.7 mg/dL\
Race: 98.2% white\
Main exclusion criteria: recent MI or stroke and insulin‐dependent diabetes mellitus\
Mean BP at entry: 163.5/101.3 mmHg\
Comorbid conditions: current smoking (20.5%), ≥ 1 plaque (64%), previous antihypertensive therapy (63%), diabetes, hyperlipidaemiaInterventions**Beta‐blocker group:**\
Atenolol 50 mg once daily\
**Calcium‐channel blocker group:**\
Lacidipine 4 mg once daily\
If satisfactory BP control was not achieved, lacidipine could be increased to 6 mg and atenolol to 100 mg (month 1), with open‐label hydrochlorothiazide added (12.5 mg/day (month 3) and 25 mg/day (month 6))OutcomesChange in mean maximum intima‐media thickness\
Plaque number\
Fatal and non‐fatal cardiovascular events\
Total mortalityNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomisation sequence computer‐generatedAllocation concealment (selection bias)Unclear riskNot adequately describedBlinding of participants and personnel (performance bias)   All outcomesLow riskParticipants and personnel blindedBlinding of outcome assessment (detection bias)   All outcomesLow riskBlind outcome assessmentIncomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up: 3.9%. Not indicated whether reasons for missing outcome data were similar across treatment groupsSelective reporting (reporting bias)Low riskAll outcomes reported as stated in protocol.Other biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[HAPPHY 1987](#CD002003-bbs2-0006){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: participants were divided into 3 groups according to predicted CHD risk based on a serum cholesterol, smoking habits, and SBP. Each risk group was divided into 3 age strata and participants in the 9 groups were allocated to treatment at random. Allocation method not described.\
Blinding: participants and providers not blinded, assessors blinded\
Loss to follow‐up: 1%\
Mean duration of follow‐up: 45.1 months\
Analyses: by intention‐to‐treatParticipantsGeographic region (% participant‐years): Belgium (0.8%), Canada (4.8%), Czechoslovakia (1.9%), Denmark (0.6%), Finland (14.0%), France (1.0%), Germany (3.3%), Greece (0.3%), Iceland (3.6%), Italy (2.7%), the Netherlands (1.6%), Norway (1.8%), Sweden (39.4%), UK (15.6%), USA (8.4%)\
Study setting: primary care\
Number of participants: 6569 (100% men)\
Age range: 40 to 64 years (mean: 52.2 years)\
Race: \> 99% white\
Exclusion criteria: history of MI, angina pectoris, stroke, malignant or secondary hypertension, malignant disease, liver cirrhosis, alcoholism or other serious diseases; people with absolute or relative contraindications to beta‐blockers (chronic obstructive lung disease) or thiazide diuretics (diabetes mellitus or gout); and people with other non‐hypertensive conditions requiring treatment with beta‐blockers or diuretics.\
Mean BP at entry: 166/107 mmHg\
BP entry criteria: diastolic BP 100 mmHg to 130 mmHg\
Comorbid conditions: smoking 2266 (34.5%)Interventions**Beta‐blocker group:**\
Step 1: atenolol 100 mg/day or metoprolol 200 mg/day; (until 1981) ‐ atenolol 200 mg/day or metoprolol 400 mg/day. Propranolol 160 mg/day given to 46 participants in 1 centre.\
**Diuretic group:**\
Step 1: bendroflumethiazide 5 mg/day or hydrochlorothiazide 50 mg/day; (until 1981) ‐ bendroflumethiazide 10 mg/day or hydrochlorothiazide 100 mg/day.\
**Additional treatment for both groups:**\
Step 2: hydralazine 75 mg/day\
Step 3: hydralazine 150 mg/day\
Step 4: step 3 + spironolactone 75 mg/day\
Step 5: step 3 + spironolactone 150 mg/day\
Step 6: step 5 + optional drug\
Percentage on assigned treatment at end of study: beta‐blocker group: 85.9% (68% as monotherapy); diuretic group: 83.4% (62% as monotherapy)OutcomesTotal mortality ‐ death from any cause\
CHD mortality ‐ fatal MI, sudden death\
CHD morbidity ‐ non‐fatal MI\
Cerebrovascular mortality ‐ fatal stroke\
Cerebrovascular morbidity ‐ non‐fatal stroke\
Cardiovascular mortality ‐ fatal stroke, MI\
Cardiovascular morbidity ‐ non‐fatal stroke, non‐fatal MINotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias)   All outcomesHigh riskParticipants and personnel not blindedBlinding of outcome assessment (detection bias)   All outcomesLow riskBlind outcome assessmentIncomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up: 1%. Not indicated whether reasons for missing outcome data were similar across treatment groups.Selective reporting (reporting bias)Low riskAll outcomes reported as stated in protocol.Other biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[INVEST 2003](#CD002003-bbs2-0007){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: Internet‐based management system automatically randomised each participant to a treatment strategy. Randomisation scheme used a standard C routine and blocked by site using randomly permuted block sizes of 4 and 6. Randomisation result was automatically stored in the central database as part of the participant\'s record and was also returned to the site investigator for electronic signature of strategy drugs in accordance with the protocol.\
Blinding: not clear whether participants were blinded; provider not blinded; assessor blinded\
Mean duration of follow‐up: 2.7 years\
Analyses: by intention‐to‐treatParticipantsGeographic location: Australia, Canada, Cuba, Dominican Republic, El Salvador, Germany, Guatemala, Hungary, Italy, Mexico, New Zealand, Panama, Turkey, US\
Study setting: primary care\
Number of participants: 22,576 (47.9% men)\
Age: ≥ 50 years (mean 66.1 years)\
Entry criteria: sitting BP \> 140/90 mmHg and documented coronary artery disease; mean entry BP 149.5/86.3 mmHg (SD 19.7/12.0).\
Race: 48.4% white, 13.4% black, 35.6% Hispanic, 0.7% Asian\
Exclusion criteria: people taking beta‐blockers within 2 weeks of randomisation or taking beta‐blockers for an MI that occurred in the previous 12 months\
Comorbid conditions: current smokers (12.4%), hypercholesterolaemia (55.8%), diabetes (28.3%), prior MI or abnormal angiogram (53.0%), previous stroke (5.1%), LVH (21.9%)Interventions**Beta‐blocker group:**\
Step 1: atenolol 50 mg/day\
(added trandolapril 2 mg/day for participants with diabetes, renal impairment, or heart failure)\
Step 2: atenolol 50 mg/day + hydrochlorothiazide 25 mg/day\
Step 3: atenolol 50 mg twice day + hydrochlorothiazide 25 mg twice daily\
Step 4: atenolol 50 mg twice day + hydrochlorothiazide 25 mg twice daily + trandolapril 2 mg/day\
Step 5: maximum tolerated or add non‐study antihypertensive medication, or both. Titration ranges: atenolol 25 mg/day to 200 mg/day, hydrochlorothiazide 12.5 mg/day to 100 mg/day, trandolapril 1 mg/day to 8 mg/day, verapamil SR 120 mg/day to 480 mg/day\
**Calcium‐channel blocker group:**\
Step 1: verapamil SR 240 mg/day\
(added trandolapril 2 mg/day for participants with diabetes, renal impairment, or heart failure)\
Step 2: verapamil SR 240 mg/day + trandolapril 2 mg/day\
Step 3: verapamil SR 180 mg twice daily + trandolapril 2 mg twice daily\
Step 4: verapamil SR 180 mg twice daily + trandolapril 2 mg twice daily + hydrochlorothiazide 25 mg/day\
Step 5: maximum tolerated or add non‐study antihypertensive medication, or both. Titration ranges: atenolol 25 mg/day to 200 mg/day, hydrochlorothiazide 12.5 mg/day to 100 mg/day, trandolapril 1 mg/day to 8 mg/day, verapamil SR 120 mg/day to 480 mg/day\
Percentage on assigned treatment at end of study: beta‐blocker group: 77.5% (18.1% as monotherapy); calcium‐channel blocker group: 81.5% (17.4% as monotherapy)OutcomesPrimary: first occurrence of death from any cause, non‐fatal MI, or non‐fatal stroke\
Secondary: all‐cause death, non‐fatal MI, non‐fatal stroke, cardiovascular death, angina, cardiovascular hospitalisations, BP control, cancer, Alzheimer\'s disease, Parkinson\'s disease, gastrointestinal bleedingNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated (assumed to be computer‐generated, because it is a blocked randomisation with varying block sizes)Allocation concealment (selection bias)Low riskCentral allocation (web‐based randomisation: an Internet‐based management system automatically randomised each participant to a treatment strategy).Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot clear whether participants were blinded; provider not blinded.Blinding of outcome assessment (detection bias)   All outcomesLow riskBlind outcome assessmentIncomplete outcome data (attrition bias)   All outcomesUnclear riskNot indicated whether reasons for missing outcome data were similar across treatment groups.Selective reporting (reporting bias)Low riskAll outcomes reported as stated in protocol.Other biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[IPPPSH 1985](#CD002003-bbs2-0008){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: random allocation of participants was achieved by providing to the investigating centres participant numbers randomised into balanced blocks each having 6 numbers. Sealed envelopes containing the treatment code were provided to each investigator.\
Loss to follow‐up: 0.6%\
Duration of follow‐up: 3 to 5 years (mean 4 years)ParticipantsGeographic region: UK (36.4%), Canada (12.0%), the Netherlands (3.6%), Israel (20.9%), Italy (11.7%), Federal Republic of Germany (15.4%)\
Number of participants: 6357 (50.2% men)\
Age range: 40 to 64 years (mean age: 52.2 years)\
Entry BP criteria: diastolic BP of 100 mmHg to 125 mmHg (Korotkoff Phase V) measured in seated position using standard mercury sphygmomanometer;  mean SBP at entry 173 mmHg (SD 18.4)\
Race:\
Exclusion criteria: past or present history of angina pectoris or MI; heart failure; relevant cardiac valvular disease; atrio‐ventricular blocks grades II and III or sick sinus syndrome; bradycardia (\< 50 beats per minute); intermittent claudication; previous cerebrovascular accident; insulin‐dependent diabetes; pregnancy; obstructive airways disease or history of bronchial asthma; renal, hepatic, gastrointestinal or any other severe disease\
Comorbid conditions: current smokers (29.1%)Interventions**Beta‐blocker group:**\
Step 1: oxprenolol slow release 160 mg/day\
**Control group:**\
Step 1: film‐coated placebo of identical appearance\
**Additional treatment for both groups:**\
Step 2: diuretic or sympatholytic or vasodilator\
Step 3: diuretic + sympatholytic, or diuretic + vasodilator, or sympatholytic + vasodilator\
Step 4: diuretic + sympatholytic + vasodilator\
During study, 30% of participants remained on beta‐blocker only while 15% remained placebo only. Total diuretic use was 67% in the beta‐blocker group and 82% in the placebo group.OutcomesCHD mortality: fatal MI, sudden death\
CHD morbidity ‐ non‐fatal MI\
Cerebrovascular mortality ‐ fatal stroke\
Cerebrovascular morbidity ‐ non‐fatal stroke\
Cardiovascular mortality\
Cardiovascular morbidity\
Total mortality\
Adverse effectsNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomisation used so assumed to be computer‐generated.Allocation concealment (selection bias)Low riskRandom allocation of participants was achieved by providing to the investigating centres participant numbers randomised into balanced blocks each having 6 numbers. Sealed envelopes containing the treatment code were provided to each investigator.Blinding of participants and personnel (performance bias)   All outcomesLow riskParticipants and personnel blindedBlinding of outcome assessment (detection bias)   All outcomesLow riskBlind outcome assessmentIncomplete outcome data (attrition bias)   All outcomesUnclear riskNot indicated whether reasons for missing outcome data were similar across treatment groups.Selective reporting (reporting bias)Low riskAll outcomes reported as stated in protocol.Other biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[LIFE 2002](#CD002003-bbs2-0009){ref-type="ref-list"}MethodsMulticentre study. 2‐week run‐in placebo period\
Randomisation: allocation numbers assigned with treatment groups using a computer‐generated allocation schedule; participants were classed as assigned to a group when they had received an allocation number. All participants received masked losartan and masked atenolol, 1 active and 1 placebo tablet.\
Blinding: participants, providers, and outcome assessors blinded\
Mean duration of follow‐up: 4.8 years (SD 0.9)\
Analyses: by intention‐to‐treatParticipantsGeographic region: Scandinavia, UK and USA\
Study setting: 945 clinical centres, mostly primary care except in Denmark where most participants were referred to hospital‐based centres.  9222 randomised but 29 participants at 1 centre excluded for irregularities. 9193 (46% men): Denmark (15%), Finland (16%), Iceland (1%), Norway (15%), Sweden (24%), UK (9%), USA (19%)\
Age range: 55 to 80 years\
BP entry criteria: DBP 95 mmHg to 115 mmHg or SBP 160 mmHg to 200 mmHg\
Race: 92% white, 6% black\
Exclusion criteria: secondary hypertension, MI or stroke within the previous 6 months; angina pectoris requiring treatment with beta‐blockers or calcium‐channel blockers; heart failure or left ventricular ejection fraction of ≤ 40%; a disorder requiring treatment with angiotensin‐II antagonist, beta‐blocker, hydrochlorothiazide, or ACE inhibitor\
Comorbid conditions: LVH (100%), smoking (16%), diabetes (13%), previous MI (16%), previous stroke (8%), atrial fibrillation (4%), peripheral vascular disease (6%)Interventions**Beta‐blocker group:**\
Step 1: atenolol 50 mg/day and losartan placebo daily\
**Angiotensin‐II antagonist group:**\
Step 2: losartan 50 mg/day and atenolol placebo daily\
**Additional treatment for both groups:**\
Step 2: add hydrochlorothiazide 12.5 mg/day\
Step 3: double dose of Step 1 therapy, atenolol 100 mg/day or losartan 100 mg/day + hydrochlorothiazide 12.5 mg/day\
Step 4: add other antihypertensive drugs excluding ACE inhibitors, angiotensin‐II antagonists and beta‐blockers\
Participants on assigned treatment at end of follow‐up: losartan group: 84%, atenolol group: 80%OutcomesPrimary: CVD mortality and mortality (composite endpoint of cardiovascular death, MI, and stroke)\
Secondary: total mortality, angina pectoris, or CHF requiring hospital admissionNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated allocation sequenceAllocation concealment (selection bias)Unclear riskMethod not adequately describedBlinding of participants and personnel (performance bias)   All outcomesLow riskParticipants and personnel blindedBlinding of outcome assessment (detection bias)   All outcomesLow riskBlind outcome assessmentIncomplete outcome data (attrition bias)   All outcomesLow riskMinimal loss to follow‐upSelective reporting (reporting bias)Low riskAll outcomes reported as stated in protocol.Other biasUnclear riskOther antihypertensive drugs were added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[MRC 1985](#CD002003-bbs2-0010){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: stratified blocks of 8 within each sex, 10‐year age group and clinic\
Blinding: participants and outcome assessors blinded, providers not blinded\
Loss to follow‐up: 19%\
Mean duration of follow‐up: 4.9 years\
Analyses: by intention‐to‐treatParticipantsGeographic region: England, Scotland, and Wales\
Study setting: primary care\
Number of participants: 17,354 (52% men)\
Age range: 35 to 64 years (mean: 52 years)\
Race: not stated\
Exclusion criteria: secondary hypertension; taking antihypertensive treatment; normally accepted indications for antihypertensive treatment (such as congestive cardiac failure) present; MI or stroke within the previous 3 months; presence of angina, intermittent claudication, diabetes, gout, bronchial asthma, serious intercurrent disease, or pregnancy\
Mean BP at entry: 162/98 mmHg\
BP entry criteria: SBP \< 200 mmHg and DBP 90 to 109 mmHg\
Comorbid conditions: smoking 29%Interventions**Control:**\
Matching placebo\
**Beta‐blocker group:**\
Propranolol up to 240 mg\
Supplementary drug: methyldopa (guanethidine used initially)\
**Diuretic group:**\
Bendrofluazide 10 mg/day\
Supplementary drug: methyldopa\
Percentage on assigned therapy at study end: beta‐blocker group: 59%, diuretic group: 61.8%, placebo group: 56.3%OutcomesTotal mortality: death from any cause\
CHD mortality ‐ fatal MI, sudden death\
CHD morbidity ‐ non‐fatal MI\
Cerebrovascular mortality ‐ fatal stroke\
Cerebrovascular morbidity ‐ non‐fatal stroke\
Cardiovascular mortality ‐ fatal stroke, MI, sudden death\
Cardiovascular morbidity ‐ non‐fatal stroke, MI, ruptured aneurysms, and othersNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskMethod not adequately describedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskParticipants blinded, but providers not blindedBlinding of outcome assessment (detection bias)   All outcomesLow riskBlind outcome assessmentIncomplete outcome data (attrition bias)   All outcomesHigh riskLoss to follow‐up (19%)Selective reporting (reporting bias)Low riskAll outcomes reported as stated in protocol.Other biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[MRCOA 1992](#CD002003-bbs2-0011){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: stratified blocks of 8 within each sex and clinic\
Blinding: participants and outcome assessors blinded, providers not blinded\
Loss to follow‐up: 25%\
Mean duration of follow‐up: 5.8 years\
Analyses: by intention‐to‐treatParticipantsGeographic region: England, Scotland, and Wales\
Study setting: primary care\
Number of participants: 4396 (42% men)\
Age range: 65 to 74 years (mean: 70.3 years)\
Race: not reported\
Exclusion criteria: known or suspected secondary hypertension; taking antihypertensive drugs; cardiac failure or any other accepted indication for antihypertensive treatment; receiving treatment for angina pectoris; history of MI or stroke within the preceding 3 months; impaired renal function; diabetic asthma; serious intercurrent disease, including malignancy known to be present at time of examination; serum potassium concentration ≤ 3.4 mmol/L or \> 5.0 mmol/L\
Mean BP at entry: 184/91 mmHg  BP entry criteria: SBP 160 mmHg to 209 mmHg and DBP \< 115 mmHg\
Comorbid conditions: smoking: 17.5%Interventions**Control group:**\
Matching placebo\
**Beta‐blocker group:**\
Step 1: atenolol 50 mg/day, may be increased to 100 mg/day\
Step 2: amiloride 2.5 mg/day + hydrochlorothiazide 25 mg/day or amiloride 5 mg/day + hydrochlorothiazide 50 mg/day\
Step 3: nifedipine up to 20 mg/day\
Step 4: other drugs\
**Diuretic group:**\
Step 1: amiloride 2.5 mg/day + hydrochlorothiazide 25 mg/day or amiloride 5 mg/day + hydrochlorothiazide 50 mg/day\
Step 2: atenolol 50 mg/day\
Step 3: nifedipine up to 20 mg/day\
Step 4: other drugs\
Percentage on assigned treatment at end of study: beta‐blocker group: 37%; diuretic group: 52%; placebo group: 47%OutcomesTotal mortality: death from any cause\
CHD mortality ‐ fatal MI, sudden death\
CHD morbidity ‐ non‐fatal MI\
Cerebrovascular mortality ‐ fatal stroke\
Cerebrovascular morbidity ‐ non‐fatal stroke\
Cardiovascular mortality ‐ fatal stroke, MI, sudden death\
Cardiovascular morbidity ‐ non‐fatal stroke, MI, CHF, TIAsNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskMethod not adequately describedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskParticipants blinded, but providers not blindedBlinding of outcome assessment (detection bias)   All outcomesLow riskBlind outcome assessmentIncomplete outcome data (attrition bias)   All outcomesHigh riskHigh loss to follow‐up (25%)Selective reporting (reporting bias)Low riskAll outcomes reported as stated in protocol.Other biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[UKPDS‐39‐1998](#CD002003-bbs2-0012){ref-type="ref-list"}MethodsMulticentre study\
Randomisation: included participants were part of the UKPDS involving allocation at random to 1 of 3 therapeutic groups: less tight control (avoid beta‐blockers and ACE inhibitors) 33%; tight control (ACE inhibitor) 33%; tight control (beta‐blocker) 33%. Allocation concealment was done with opaque, sealed envelopes with a check maintained on numerical sequence, dates of opening and results.\
Blinding: participants, providers, and assessors not blinded\
Loss to follow‐up: 4%\
Median duration of follow‐up: 8.4 years\
Analyses: by intention‐to‐treatParticipantsGeographic region: England, Scotland, and Northern Ireland\
Study setting: primary care\
Number of participants: 758 (54% men)\
Age range: 25 to 65 years (mean: 56.4 years)\
Race: white 651 (86%); black 62 (8%); Asian‐Indian 39 (5%); other 6 (1%)\
Exclusion criteria: ketonuria \> 3 mmol/L; history of MI in the previous year; current angina or heart failure; \> 1 vascular episode; serum creatinine concentration \> 175 μmol/L; retinopathy requiring laser treatment; malignant hypertension; uncorrected endocrine abnormality; occupation which would preclude insulin treatment (such as heavy goods vehicle driver); a severe concurrent illness likely to limit life or require extensive treatment; or inadequate understanding or unwillingness to enter the study\
Mean BP at entry: 159/93 mmHg  BP entry criteria: SBP ≥ 160 mmHg or DBP ≥ 90 mmHg, or both; or SBP ≥ 150 mmHg or DBP ≥ 85 mmHg in participants receiving antihypertensive medication\
Comorbid conditions: smoking: 171 (23%)Interventions**Beta‐blocker group:**\
Step 1: atenolol 50 mg/day, increasing to 100 mg/day\
**ACE inhibitor group:**\
Step 1: captopril 25 mg twice daily, increasing to 50 mg twice daily\
**Additional treatment for both groups:**\
Step 2: frusemide 20 mg/day (maximum 40 mg twice daily)\
Step 3: nifedipine slow release 10 mg (maximum 40 mg) twice daily\
Step 4: methyldopa 250 mg (maximum 500 mg) twice daily; prazosin 1 mg (maximum 5 mg) 3 times daily\
Participants remaining on assigned therapy at study end: beta‐blocker group: 65%, ACE inhibitor group: 78%OutcomesTotal mortality: death from any cause\
CHD mortality ‐ fatal MI, sudden death\
CHD morbidity ‐ non‐fatal MI\
Cerebrovascular mortality ‐ fatal stroke\
Cerebrovascular morbidity ‐ non‐fatal stroke\
Cardiovascular mortality ‐ fatal stroke, MI, sudden death\
Cardiovascular morbidity ‐ non‐fatal stroke, MI, heart failureNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated random sequenceAllocation concealment (selection bias)Low riskAllocation concealment with opaque, sealed envelopes with a check maintained on numerical sequence, until dates of opening and resultsBlinding of participants and personnel (performance bias)   All outcomesHigh riskParticipants and providers not blindedBlinding of outcome assessment (detection bias)   All outcomesLow riskNo blinding of outcome assessment, but the outcome assessed (i.e. death) is unlikely to be influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesUnclear riskNot indicated whether reasons for missing outcome data were similar across treatment groups.Selective reporting (reporting bias)Low riskAll outcomes reported as stated in protocol.Other biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[VA COOP 1982](#CD002003-bbs2-0013){ref-type="ref-list"}MethodsMulticentre study  Randomisation: described as randomised controlled trial, but method of allocating participants to treatment not described\
Blinding: participants, providers, and assessors blinded\
Loss to follow‐up: 8%\
Mean duration of follow‐up: 12 months\
Participants withdrawn from the study for uncontrolled BP not included in the analysisParticipantsGeographic region: USA\
Study setting: hospital\
Number of participants: 683 (all men)\
Age range: 21 to 65 years (mean: 49.6 years)\
Race: 43% white and 57% black\
BP at entry: DBP 95 to 104 mmHg\
Comorbid conditions: not describedInterventions**Beta‐blocker group:**\
Propranolol 40 mg twice daily, increasing to 640 mg/day\
**Diuretic group:**\
Hydrochlorothiazide 25 mg twice daily, increasing to 200 mg/day\
Participants still on assigned baseline therapy at study end: beta‐blocker group, 39%, diuretic group: 52%OutcomesTotal mortality\
Cerebrovascular disease\
CHDNotesParticipants were withdrawn from the study if, on any follow‐up visit, DBP ≥ 120 mmHg***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias)   All outcomesLow riskParticipants and providers blindedBlinding of outcome assessment (detection bias)   All outcomesLow riskOutcome assessors blindedIncomplete outcome data (attrition bias)   All outcomesLow risk\"A total of 73 (10.7%) of the patients were dropped from the study after randomization. Of these, 42 (57.5%) were in the propranolol group and 31 were taking hydrochlorothiazide. The difference was not significant\"\
Analyses by intention‐to‐treatSelective reporting (reporting bias)Unclear riskNo access to study protocol.Other biasUnclear riskOther antihypertensive drugs added to randomly allocated treatment to control BP. The observed effects may equally have resulted from the different additional drugs.[^1]

Characteristics of excluded studies \[ordered by study ID\] {#CD002003-sec2-0021}
===========================================================

StudyReason for exclusion[ACCORD 2010](#CD002003-bbs2-0014){ref-type="ref-list"}Study designed to test the effect of BP lowering in addition to glycaemic control in people with diabetes. Participants were assigned to 2 BP treatment goals ‐ intensive (SBP \< 120 mmHg) or standard (SBP \< 140 mmHg). Various classes of antihypertensive drugs used but recommended start with combination of diuretic and ACE inhibitor or beta‐blocker. Beta‐blockers not first‐line or monotherapy.[ADaPT 2008](#CD002003-bbs2-0015){ref-type="ref-list"}Observational study conducted in primary care compared ACE inhibitor‐based treatment (ramipril) with a treatment based on diuretics or beta‐blockers. Not randomised.[APSIS 2006](#CD002003-bbs2-0016){ref-type="ref-list"}Study compared verapamil or metoprolol in people with stable angina pectoris. Not all participants had hypertension (27%). Mean baseline BP not given.[CAPP 1999](#CD002003-bbs2-0017){ref-type="ref-list"}This study compared the effects of ACE inhibitors and conventional therapy (diuretics and beta‐blockers) on cardiovascular morbidity and mortality in people with hypertension. Findings were not reported separately for beta‐blockers.[CAPRICORN 2001](#CD002003-bbs2-0018){ref-type="ref-list"}Trial evaluated the effects of carvedilol with placebo on survival in post‐MI participants with left ventricular dysfunction with or without symptomatic heart failure. All participants given ACE inhibitors for at least 48 hours before randomisation. Not all participants had hypertension (54%) and beta‐blockers not first‐line or monotherapy.[CARDHIAC 2008](#CD002003-bbs2-0019){ref-type="ref-list"}Study examined effects of doxazosin GITS and atenolol on 3 measures of target organ damage in people with type 2 diabetes and hypertension. Participants received ACE inhibitors or ARB and diuretic initially before receiving doxazosin GITS and atenolol. Beta‐blockers not first‐line or monotherapy.[CHHIPS 2009](#CD002003-bbs2-0020){ref-type="ref-list"}This RCT, which was conducted in 6 centres in the UK, evaluated the effects of active treatment with the ACE inhibitor, lisinopril, or beta‐blocker, labetalol, compared to placebo in people aged \> 18 years with a clinical diagnosis of suspected stroke (with symptom onset \< 36 hours) and hypertension (defined as SBP \> 160 mmHg). After 2 weeks of treatment, study participants were routinely started on an ACE inhibitor with or without a diuretic irrespective of whether they had normal BP or hypertension, unless they were deemed to be unsuitable for such therapy. Decisions with regard to future antihypertensive therapy were delayed until the end of the trial intervention (2 weeks). The proportion of participants on assigned treatment at the end of the study was 71% in the beta‐blocker group, 68% in the ACE inhibitor group, and 80% in the placebo group. 172 participants, with mean age 74 years, were enrolled and the study reported mortality data at 3 months. We excluded this study because of the short duration (i.e. only 2 weeks) of relevant interventions.[CIBIS‐II 1999](#CD002003-bbs2-0021){ref-type="ref-list"}Trial compared bisoprolol and placebo in people with heart failure receiving standard therapy with an ACE inhibitor and diuretic. Not all participants had hypertension (mean baseline BP 139/80 mmHg) and beta‐blocker not first‐line or monotherapy.[COMET 2003](#CD002003-bbs2-0022){ref-type="ref-list"}Trial compared carvedilol and metoprolol in people with chronic heart failure. Not all had hypertension (36%). Mean baseline BP 126/77 mmHg.[CONVINCE 1998](#CD002003-bbs2-0023){ref-type="ref-list"}The Controlled ONset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial is a randomised, prospective, double‐blind, parallel‐group, 2‐arm, multicentre, international trial. The study recruited 15,000 people with hypertension, aged \> 55 years, with an established second risk factor for cardiovascular disease and followed them for 5 years to compare the effects of controlled onset‐extended release verapamil 180 mg/day and hydrochlorothiazide 12.5 mg/day or atenolol 50 mg/day. Data has not been reported separately for hydrochlorothiazide and atenolol.[COPE 2005](#CD002003-bbs2-0024){ref-type="ref-list"}Study compared a combination of ARB, beta‐blocker, or thiazide diuretic in addition to a calcium‐channel blocker, benidipine hydrochloride, in Japanese people with hypertension. Beta‐blockers not first‐line treatment or monotherapy.  [COPERNICUS 2004](#CD002003-bbs2-0025){ref-type="ref-list"}Study compared carvedilol vs placebo in people with chronic heart failure and receiving spironolactone or not at baseline. Not all participants had hypertension (mean baseline BP 123/76 mmHg).[COSMOS 2010](#CD002003-bbs2-0026){ref-type="ref-list"}People with stage 1 or 2 hypertension were randomised evenly to 1 of 15 groups for 6 weeks: extended‐release carvedilol (carvedilol CR) monotherapy 20 mg/day, 40 mg/day, or 80 mg/day; lisinopril monotherapy 10 mg/day, 20 mg/day, or 40 mg/day; or 1 of 9 combinations of carvedilol CR + lisinopril initiated simultaneously. The study has not reported effects on mortality or cardiovascular endpoints.[Dietz 2008](#CD002003-bbs2-0027){ref-type="ref-list"}This RCT was conducted in 85 centres in China, Germany, India, South Africa, Spain, and Turkey. People with hypertension (defined as mean sitting DBP 95 mmHg to 110 mmHg) were randomised to once‐daily aliskiren 150 mg (231 participants), atenolol 50 mg (231 participants), or the combination (150/50 mg; 232 participants) for 6 weeks, followed by a further 6 weeks on double the initial doses of aliskiren and atenolol. Aliskiren is the first direct renin inhibitor to be approved for the treatment of hypertension. The proportion of participants on assigned treatment at the end of the study was 92.2% in the beta‐blocker group, 91.3% in the direct renin inhibitor group, and 88.4% in the combination group. The trial followed up 694 participants (mean age 55.2 years, 23% aged ≥ 65 years) for 12 weeks. We excluded this study because of the short duration (i.e. only 12 weeks) of relevant interventions.[Dutch TIA 1993](#CD002003-bbs2-0028){ref-type="ref-list"}The trial evaluated the effects of a beta‐blocker (atenolol) in people after a transient ischaemic attack or non‐disabling ischaemic stroke in 56 collaborative centres in the Netherlands. Participants were randomised to atenolol or a matching placebo. The proportion of participants on assigned treatment in the beta‐blocker group was 71% at 2 years (and 64% at 3 years) and in the placebo group was 75% at 2 years (and 68% at 3 years). The trial followed up 1473 participants (52% aged \> 65 years) for a mean duration of 2.7 years. We excluded the trial because only 29% of participants had hypertension at baseline.[GEMINI 2008](#CD002003-bbs2-0029){ref-type="ref-list"}Trial compared effects of carvedilol with metoprolol on glycaemic control in people with hypertension and type‐2 diabetes. BP was stabilised using ACE inhibitors or ARB antihypertensive regimens (or both) prior to randomisation. Beta‐blockers not first‐line or monotherapy.[IMPACT‐HF 2004](#CD002003-bbs2-0030){ref-type="ref-list"}Study assessed the use of carvedilol therapy initiated before discharge in people hospitalised with heart failure compared with \'usual care\'. Not all participants had hypertension (64%). Baseline mean BP 124/69.5 mmHg)[MAPHY 1988](#CD002003-bbs2-0031){ref-type="ref-list"}This multicentre study was a subset of the HAPPHY trial. Analysis take into consideration only 1 of the 2 beta‐blockers (metoprolol). Including this trial alongside the HAPPHY trial would count those participants twice.[Marazzi 2011](#CD002003-bbs2-0032){ref-type="ref-list"}This trial compared the effects of long‐term treatment with nebivolol vs carvedilol on left ventricular ejection fraction in people with hypertensive chronic heart failure. We excluded this study because the majority of participants were already taking other antihypertensives at baseline, mainly ACE inhibitors.[MERIT‐HF 2002](#CD002003-bbs2-0033){ref-type="ref-list"}Trial evaluated metoprolol compared to placebo added to standard therapy in people with heart failure. Not all participants had hypertension (44%). Mean baseline BP not given.[Nilsson 2007](#CD002003-bbs2-0034){ref-type="ref-list"}This trial compared 2 first‐line antihypertensive therapies for initiating treatment in hypertension, i.e. the ACE inhibitor zofenopril and the beta‐blocker atenolol. The study has not reported effects on mortality or cardiovascular endpoints.[NORDIL 2000](#CD002003-bbs2-0035){ref-type="ref-list"}The Nordic Diltiazem (NORDIL) study enrolled 10,881 people with hypertension aged 50 to 74 years at health centres in Norway and Sweden and randomly assigned them to either diltiazem, or diuretics with/without beta‐blockers. Morbidity and mortality were not reported separately for participants assigned to beta‐blocker therapy.[REASON 2009](#CD002003-bbs2-0036){ref-type="ref-list"}Trial compared the effects of atenolol and perindopril/indapamide on BP and carotid‐femoral pulse wave velocity, which is a marker for aortic stiffness and arterial wall alterations. No morbidity or mortality data reported.[RESOLVD 2000](#CD002003-bbs2-0037){ref-type="ref-list"}Trial compared metoprolol or placebo in people with heart failure who had received treatment with either an ACE inhibitor (enalapril) or ARB (candesartan) or both for 5 months prior to trial commencement (+ a diuretic in 84% of participants). Beta‐blocker not first‐line or monotherapy.[SENIORS 2005](#CD002003-bbs2-0038){ref-type="ref-list"}Study compared the effects of nebivolol with placebo, in addition to standard therapy, in elderly people with chronic heart failure. Not all participants had hypertension (62%). Mean baseline BP 139/81 mmHg.[STOP 1991](#CD002003-bbs2-0039){ref-type="ref-list"}This study compared the effects of active hypertensive treatment (1 of 3 beta‐blockers or a diuretic) and placebo in elderly people with hypertension. Morbidity and mortality were not reported separately for participants assigned to beta‐blocker therapy.[STOP‐2 1999](#CD002003-bbs2-0040){ref-type="ref-list"}Conventional antihypertensive drugs (1 of 3 beta‐blockers or a diuretic) were compared with newer agents, ACE inhibitors and calcium‐channel blockers. Findings were not reported separately for participants taking beta‐blockers.[TEST 1995](#CD002003-bbs2-0041){ref-type="ref-list"}The trial was conducted in 21 centres in Sweden between July 1988 and June 1992. The study evaluated the effects of a beta‐blocker (atenolol) in people aged \> 40 years enrolled within 3 weeks of a stroke or transient ischaemic attack. Participants were randomised to atenolol or a matching placebo. The proportion of participants on assigned treatment at the end of the study not stated. The trial followed up 720 participants (mean age 70.4 years) for a mean duration of 2.5 years. We excluded this study because not all participants had hypertension at baseline.[^2]

We have decided to have clearly defined strict eligibility criteria regarding duration of treatment, which we have now set at one year or more on trial medications. In the protocol and initial version of the review published in 2007, duration of treatment was not included as a criterion for eligibility. We have now used the \'Risk of bias\' tool as described in Chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#CD002003-bbs2-0061){ref-type="ref-list"}). This tool was not yet developed when the protocol was written.

CSW and HB screened the search output, selected studies, assessed the risk of bias, and extracted data. At each stage, the two review authors resolved differences by discussion and consensus; with arbitration by JV.

CW conducted the analyses.

All review authors read and approved the final version before submission.

CSW and HB contributed equally to this review and share first authorship.
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South African Medical Research Council (CSW), South Africa.Stellenbosch University (CSW, JV), South Africa.University of the Western Cape (HB), South Africa.University of Cape Town (BMM, LHO), South Africa.
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No sources of support supplied

We have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of this systematic review.

[^1]: ACE: angiotensin‐converting enzyme; BP: blood pressure; CHD: coronary heart disease; CHF: congestive heart failure; CVD: cardiovascular disease; DBP: diastolic blood pressure; LVH: left ventricular hypertrophy; MI: myocardial infarction; SBP: systolic blood pressure; SD: standard deviation; SR: sustained release; TIA: transient ischaemic attack.

[^2]: ACE: angiotensin‐converting enzyme; ARB: angiotensin receptor blocker; BP: blood pressure; DBP: diastolic blood pressure; MI: myocardial infarction; RCT: randomised controlled trial; SBP: systolic blood pressure.
